<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Coll Nutr</journal-id><journal-id journal-id-type="iso-abbrev">J Am Coll Nutr</journal-id><journal-id journal-id-type="archive">UACN</journal-id><journal-id journal-id-type="publisher-id">uacn20</journal-id><journal-title-group><journal-title>Journal of the American College of Nutrition</journal-title></journal-title-group><issn pub-type="ppub">0731-5724</issn><issn pub-type="epub">1541-1087</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28976265</article-id><article-id pub-id-type="pmc">5817641</article-id><article-id pub-id-type="publisher-id">1355761</article-id><article-id pub-id-type="doi">10.1080/07315724.2017.1355761</article-id><article-categories><subj-group subj-group-type="article-type"><subject>Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Evolution of Serum 25OHD in Response to Vitamin D<sub>3</sub>&#x02013;Fortified Yogurts Consumed by Healthy Menopausal Women: A 6-Month Randomized Controlled Trial Assessing the Interactions between Doses, Baseline Vitamin D Status, and Seasonality</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bonjour</surname><given-names>Jean-Philippe</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="af0001"/><xref ref-type="corresp" rid="an0001"/></contrib><contrib contrib-type="author"><name><surname>Dontot-Payen</surname><given-names>Flore</given-names></name><xref ref-type="aff" rid="af0002"/></contrib><contrib contrib-type="author"><name><surname>Rouy</surname><given-names>Emilien</given-names></name><xref ref-type="aff" rid="af0002"/></contrib><contrib contrib-type="author"><name><surname>Walrand</surname><given-names>Stephane</given-names></name><xref ref-type="aff" rid="af0003"/></contrib><contrib contrib-type="author"><name><surname>Rousseau</surname><given-names>Brigitte</given-names></name><xref ref-type="aff" rid="af0002"/></contrib><aff id="af0001">
<label><sup>a</sup></label>
<institution><named-content content-type="department">Division of Bone Diseases</named-content>, <named-content content-type="institution-name">University Hospitals and Faculty of Medicine</named-content></institution>, <named-content content-type="city">Geneva</named-content>, <country>Switzerland</country>
</aff><aff id="af0002">
<label><sup>b</sup></label>
<institution><named-content content-type="department">Groupe de Recherche Nutritionnelle</named-content></institution>, Yoplait, <named-content content-type="city">Boulogne</named-content>, <country>France</country>
</aff><aff id="af0003">
<label><sup>c</sup></label>
<institution><named-content content-type="department">INRA, UMR 1019, UNH, CRNH Auvergne</named-content></institution>, <named-content content-type="city">Clermont-Ferrand</named-content>, <country>France</country>
</aff></contrib-group><author-notes><corresp id="an0001"><bold>CONTACT</bold> Jean-Philippe Bonjour, MD <email xlink:href="jean-philippe.bonjour@unige.ch">jean-philippe.bonjour@unige.ch</email><institution><named-content content-type="department">Division of Bone Diseases</named-content>, <named-content content-type="institution-name">Geneva University Hospitals and Faculty of Medicine, Rue Gabrielle Perret-Gentil 4</named-content></institution>, <named-content content-type="postal-code">CH&#x02013;1211</named-content><named-content content-type="city">Geneva</named-content>, <country>Switzerland</country></corresp><fn><p>ClinicalTrials.gov ID: NCT02534064</p></fn></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>04</day><month>10</month><year>2017</year></pub-date><volume>37</volume><issue>1</issue><fpage seq="5">34</fpage><lpage>43</lpage><history><date date-type="received"><day>09</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>12</day><month>7</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="description"> &#x000a9; Jean-Philippe Bonjour, Flore Dontot-Payen, Emilien Rouy, Stephane Walrand, and Brigitte Rousseau <copyright-statement>--><copyright-statement>&#x000a9; 2018 The Author(s). Published with license by Taylor &#x00026; Francis</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access"><license-p>This is an Open Access article. Non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly attributed, cited, and is not altered, transformed, or built upon in any way, is permitted. The moral rights of the named author(s) have been asserted.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="uacn-37-1355761.pdf"/><abstract><title>ABSTRACT</title><p>
<bold>Background:</bold> Adequate vitamin D status contributes to bone fragility risk reduction and possibly other pathological conditions that occur with aging. In response to pharmaceutical vitamin D<sub>3</sub> supplements, several studies have documented the influence of doses, baseline status, and seasonality on serum 25-hydroyvitamin D (s25OHD).</p><p>
<bold>Objective:</bold> Using fortified yogurt, we investigated in one randomized controlled trial how both baseline status, as assessed by measuring s25OHD prior the onset of the trial, and the season of enrollment quantitatively influenced the response to the supplemented (Suppl.) of vitamin D<sub>3</sub> (VitD<sub>3</sub>) in healthy community-dwelling women.</p><p>
<bold>Methods:</bold> A 24-week controlled trial was conducted in menopausal women (mean age: 61.5). Participants were randomized into 3 groups (Gr): Gr.Suppl.0, time controls maintaining dietary habits; Gr.Suppl.5 and Gr.Suppl.10 consuming one and two 125-g servings of VitD<sub>3</sub>-fortified yogurts with 5- and 10-&#x000b5;g daily doses, respectively. The 16 intervention weeks lasted from early January to mid-August, the 8 follow-up weeks, without product, from late August to mid-October. Before enrollment, subjects were randomized into 2 s25OHD strata: low stratum (LoStr): 25&#x02013;50 nmol/L; high stratum (HiStr): &#x0003e;50&#x02013;75&#x000a0;nmol/L.</p><p>
<bold>Results:</bold> All enrolled participants adhered to the protocol throughout the 24-week study: Gr.Suppl.0 (<italic>n</italic> = 45), Gr.Suppl.5 (<italic>n</italic> = 44), and Gr.Suppl.10 (<italic>n</italic> = 44). Over the 16 intervention and 8 follow-up weeks, s25OHD increased in both supplemented groups, more in Gr.Suppl.10 than in Gr.Suppl.5. At the end of the intervention, the subject proportion with s25OHD &#x02265; 50 nmol/L was 37.8, 54.5, and 63.6% in Gr.Suppl.0, Gr.Suppl.5, and Gr.Suppl.10, respectively. The constant rate of s25OHD per supplemental VitD<sub>3</sub> microgram was greater in LoStr than HiStr. The s25OHD increase was greater with late (mid-March) than early (mid-January) inclusion.</p><p>
<bold>Conclusion:</bold> This randomized trial demonstrates (1) a dose-dependent s25OHD improvement related to fortified yogurt consumption; (2) an inversely baseline-dependent increase in s25OHD; and (3) a seasonal effect that highlights the importance of VitD<sub>3</sub>-fortified foods during winter, even at 5 &#x000b5;g/d, in healthy menopausal women.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Nutritional intervention</kwd><kwd>menopausal women</kwd><kwd>vitamin D<sub>3</sub>&#x02013;fortified yogurts</kwd><kwd>serum 25OHD dose&#x02013;response</kwd><kwd>seasonality interaction</kwd></kwd-group><counts><fig-count count="5"/><table-count count="4"/><equation-count count="0"/><ref-count count="46"/><page-count count="10"/></counts></article-meta></front><body><sec sec-type="intro" id="s0001"><title>Introduction</title><p>Improving the vitamin D status of the general population is recognized as an important public health commitment <xref rid="cit0001" ref-type="bibr">[1&#x02013;5]</xref>. This status can be assessed by the measurement of its main circulating metabolite, namely, serum 25-hydroxyvitamin D (s25OHD). Among adults, the risk of vitamin D insufficiency (s25OHD &#x0003c; 50&#x000a0;nmol/L), even deficiency (s25OHD &#x0003c; 25&#x000a0;nmol/L), increases with age <xref rid="cit0002" ref-type="bibr">[2,6]</xref>.</p><p>The greater risk appears to be in elderly population, particularly those living in institutions and who, for various reasons, have a limited access to sun exposure that is not compensated by an adequate vitamin D intake <xref rid="cit0007" ref-type="bibr">[7]</xref>. Nevertheless, younger populations, such as menopausal women in their late 60s and early 70s, also include a certain number of individuals with s25OHD between 25 and 50&#x000a0;nmol/L, a status that corresponds to vitamin D insufficiency <xref rid="cit0004" ref-type="bibr">[4,8]</xref>. The best-documented outcome of this inadequate supply is the risk of fragility fractures, which increases with advancing age <xref rid="cit0004" ref-type="bibr">[4,8&#x02013;10]</xref>.</p><p>The limited vitamin D supply provided by most consumed foods in industrialized countries requires an alternative strategy for preventing the development of insufficient or deficient status of this micronutrient in the general population. Fostering sun exposure might theoretically represent an alternative strategy, because ultraviolet radiation of 290- to 315-nm wavelength (ultraviolet B) stimulates the cutaneous photosynthesis of vitamin D<sub>3</sub> (cholecalciferol) from 7-dehydrocholesterol <xref rid="cit0011" ref-type="bibr">[11]</xref>. However, this potential alternative is far from being straightforward. Indeed, the production of vitamin D<sub>3</sub> (VitD<sub>3</sub>) by the skin is dependent on several factors, including seasonality, geographical location (latitude, altitude), ozone layer, cutaneous melanin pigment, aging, obesity, and body mass index (BMI), as well as the widespread practice of sun avoidance and/or use of protection creams to curtail skin cancer risk <xref rid="cit0008" ref-type="bibr">[8,11&#x02013;15]</xref>. Therefore, taking all of these various determinants into account, it is difficult to recommend the appropriate sunlight exposure &#x0201c;dose&#x0201c; in order to achieve a sufficient vitamin D status without increasing skin cancer risk <xref rid="cit0015" ref-type="bibr">[15&#x02013;17]</xref>.</p><p>It is easier to determine the sufficient amount of vitamin D<sub>3</sub>, whether taken orally in pharmaceutical preparations or in fortified foods. Nevertheless, the impact of vitamin D<sub>3</sub> intake on its status depends upon several factors, including (1) dosage; (2) baseline s25OHD level; and (3) season of the year. These 3 determinants have been identified in several observational or interventional studies <xref rid="cit0002" ref-type="bibr">[2,5,8,12&#x02013;14,18&#x02013;27]</xref>. How these 3 determinants quantitatively interact remains to be documented in a single prospective study including well-characterized subjects.</p><p>In order to test these assumptions, we designed a 24-week randomized controlled trial to quantitatively assess the evolution of s25OHD in response to 2 amounts of vitamin D<sub>3</sub> as supplied in fortified yogurt in a cohort of healthy menopausal women. The study was designed to highlight the interaction of the s25OHD response with the baseline vitamin D status and the influence of seasonality.</p></sec><sec sec-type="materials|methods" id="s0002"><title>Materials and methods</title><sec id="s0002-0001"><title>Ethical aspects</title><p>The study was carried out in accordance with the Declaration of Helsinki as modified in Fortaleza (Brazil) in October 2013 and the recommendations on Good Clinical Practice (ICH E6) and any applicable local regulatory requirements. The study began upon receipt of the approval of both the Ethics Committee (&#x0201c;Comit&#x000e9; de Protection des Personnes&#x0201d; and the French Health Authorities (Agence nationale de s&#x000e9;curit&#x000e9; du m&#x000e9;dicament et des produits de sant&#x000e9;).</p></sec><sec id="s0002-0002"><title>Participants</title><p>Participants were recruited among community-dwelling women in the Auvergne&#x02013;Rh&#x000f4;ne&#x02013;Alpes region in France. Only study-specific recruitment tools approved by the European Community were used. These recruitment tools included a volunteer database from the General Clinical Research Center (GCRC), Eurofins-Optimed (Gi&#x000e8;res, France); regional newspaper advertisements with specific press inserts; radio spots and broadcast messages; posters; mailings; and the GCRC recruitment website. Two hundred eighty-eight volunteers expressed interest in participating. The screening procedure occurred within 3&#x000a0;weeks before the intervention; 140 participants met the study design criteria and were enrolled between January 7 and April 22, 2015.</p></sec><sec id="s0002-0003"><title>Inclusion criteria</title><p>Inclusion criteria were as follows: women aged between 55 and 75&#x000a0;years with menopause for &#x02265;5&#x000a0;years; informed consent obtained in conformity with the European Directive and French Code of Public Health; and BMI ranging from 18 to 28&#x000a0;kg/m<sup>2</sup>.</p></sec><sec id="s0002-0004"><title>Exclusion criteria</title><p>Exclusion criteria included the use of any form of supplemental vitamin D whether as pharmaceutical preparation or through the intake of fortified foods such as milk, dairy products, oil, and tofu during the 6&#x000a0;months preceding the trial; functional disability or confinement to bed; concomitant bone disease or any illness affecting calcium&#x02013;inorganic phosphate (Ca-Pi) metabolism such as primary hyperparathyroidism, osteoporotic fracture during the year preceding the study, chronic gastrointestinal disease, chronic renal failure, hepatic and cardiac failure, or cancer; treatment during the last 6&#x000a0;months for osteoporosis or other bone disease, including pharmaceutical agents such as bisphosphonates, raloxifene, teriparatide, strontium ranelate, and denosumab; current glucocorticoid treatment; ongoing hormonal replacement therapy; lactose intolerance or any substantial food allergy; and participation in a clinical trial during the 3&#x000a0;months preceding entry into the study.</p></sec><sec id="s0002-0005"><title>Design and conduct of the trial</title><p>The study was a randomized, open-label controlled trial conducted in one single GCRC located in Gi&#x000e8;res, (Is&#x000e8;re Departement of the Auvergne&#x02013;Rh&#x000f4;ne&#x02013;Alpes region), France.</p><p>The aim was to evaluate the effects of a daily consumption of 1 or 2 yogurts fortified with vitamin D and calcium on the evolution of 25OHD during 16&#x000a0;weeks. One 125-g yogurt pot provided 5 &#x000b5;g VitD<sub>3</sub>, 400&#x000a0;mg calcium, 5&#x000a0;g protein, and 88&#x000a0;kcal energy.</p><p>A randomization list was used by the GCRC to distribute the participants into 3 groups:<list list-type="simple"><list-item><label>&#x02022;</label><p>Gr.Suppl.0: Parallel time controls that were advised not to change their dietary habits during the 24-week study.</p></list-item><list-item><label>&#x02022;</label><p>Gr.Suppl.5: Consumption of 1 yogurt per day during 16&#x000a0;weeks followed by 8&#x000a0;weeks without product.</p></list-item><list-item><label>&#x02022;</label><p>Gr.Suppl.10: Consumption of 2 yogurts per day during 16&#x000a0;weeks followed by 8&#x000a0;weeks without product.</p></list-item></list>
</p><p>Ambulatory visits at the clinical research center were scheduled at inclusion or baseline (BSL) and after weeks 4 (WK4), 8 (WK8), 12 (WK12), 16 (WK16), and 24 (WK24). At each visit, a physical examination was performed, including measurement of body weight, waist circumference, blood pressure, and heart rate and blood sampling. Participants provided a diary reporting information on compliance and product acceptability (see below).</p></sec><sec id="s0002-0006"><title>Adherence assessment and acceptability evaluation</title><p>Participants randomized to consume 1 (Gr.Suppl.5, <italic>n</italic> = 44) or 2 yogurts (Gr.Suppl.10, <italic>n</italic> = 44) per day were asked to complete questionnaires regarding adherence and acceptability of the product. Adherence was noted each day by the participants in a diary. Furthermore, they were asked to keep the yogurt lids. Adherence to or compliance with the intervention in Gr.Suppl.5 and Gr.Suppl.10 was assessed by computing the number of yogurt pot lids returned by the participants at each visit from WK4 to WK16. Adherence was expressed as the ratio (%) of pots consumed to pots distributed for each period of 4&#x000a0;weeks.</p><p>Acceptability was assessed at weeks 4, 8, 12, and 16 following the onset of the intervention. A scale from 0 to 10 (<italic>do not agree at all</italic> = 0; <italic>completely agree</italic> = 10) was completed in response to the following questions: &#x0201c;Does the dairy product have a pleasant taste?&#x0201d; &#x0201c;Is its size suitable for my appetite?&#x0201d; &#x0201c;Is consumption at a rate of 2 pots per day too restrictive, that is, does it limit the food intake at lunch and dinner?&#x0201d; &#x0201c;Am I tired of consuming it?&#x0201d; The investigator noted the responses for the last 4 weeks in the appropriate section of the case report form.</p></sec><sec id="s0002-0007"><title>Sun exposure and vitamin D supplies</title><p>Participants were asked to limit daily sun exposure with bare arms or legs to no longer than 20 minutes and not to attend tanning centers. The subjects had to report whether at any time during the 24 investigation weeks they spent more than 20&#x000a0;minutes daily with uncovered arms exposed to the sun or traveled to regions with ultraviolet exposure greater than in the investigation area. The dietary vitamin D supplies were assessed using a questionnaire on the consumption of foods containing vitamin D <xref rid="cit0028" ref-type="bibr">[28]</xref> and was completed at BSL, WK16, and WK 24.</p></sec><sec id="s0002-0008"><title>Biochemical analysis</title><p>Blood samples were collected in the morning after an overnight fast. They were stored at &#x02212;70&#x000b0;C until analysis. s25OHD was determined by 2&#x000a0;successive methods. For the screening samples, s25OHD was measured by an automated electroluminescence immunoassay (Cobas 6000, Roche Diagnostics, Rotkreuz, Switzerland). Then, for all samples collected from BSL to WK24 and thus included in the statistical analysis of the results, serum 25OHD was measured by enzyme-linked immunosorbent assay (Promokine, Heidelberg, Germany) on a Bio-Rad Microtech Microplate Reader (Hercules, CA). In other words, the screening s25OHD values were measured several days before the baseline measurements.</p><p>The intra-assay and interassay variations were less than 7.0% for both assays. All analytical measurements from BSL to WK24 were run together. Each sample was measured in duplicate.</p><p>The option to shift from electroluminescence immunoassay used at screening to enzyme-linked immunosorbent assay used for the whole randomized controlled trial was warranted by the apparent greater sensitivity of the latter method. This shift resulted in an expansion of the s25OHD range from 21&#x02013;76 (screening) to 7&#x02013;74 (BSL) nmol/L as determined in the 133 samples collected from all participants included who were compliant during the 24-week trial. The correlation coefficient (<italic>r</italic>) between the 2 methods was 0.765 as assessed in blood collected at screening and at baseline (mean time interval: 6.4&#x000a0;days) in the 133 subjects who participated in the 24-week randomized study.</p></sec><sec id="s0002-0009"><title>Statistical analysis</title><p>Determination of the sample size was estimated in order to highlight a difference in serum 25OHD of 7.5 nmol/L between the yogurt-consuming groups (active) and the control group (primary outcome). Taking into account a serum 25OHD standard deviation (SD) of 10&#x000a0;nmol/L, in order to achieve a power of 90% and a 2-sided &#x003b1; of 5%, the overall number of subjects to be included was estimated at 105; that is, 35 per group. With an anticipated dropout rate of 25%, 140&#x000a0;participants were eventually randomized; that is, 46, 47, and 47 in Gr.Suppl.0, Gr.Suppl.5, and Gr.Suppl.10, respectively. Seven subjects dropped out before the onset of the intervention: 1, 3, and 3 in Gr.Suppl.0, Gr.Suppl.5, and Gr.Suppl.10, respectively. Statistical analysis was applied to all included and compliant subjects (<italic>n</italic> = 133) and in addition to 2 subgroups stratified according to s25OHD from 25 to 50&#x000a0;nmol/L and from &#x02265;50 to 75&#x000a0;nmol/L as measured in the screening samples. This stratification generated the following 2 subpopulations: low stratum (LoStr), <italic>n</italic> = 53; high stratum (HiStr), <italic>n</italic> = 80 (secondary outcome). Over the 16 intervention weeks and the following 8 weeks after discontinuation, the differences in the time course and the tested products for s25OHD were evaluated by repeated measures analysis of variance (ANOVA) with adjustment by Tukey's test. Student's <italic>t</italic> test was used for changes from BSL to WK16 as well as the Wilkoxon signed rank test whenever the variable was not normally distributed.</p><p>Over the first 8&#x000a0;weeks of the intervention (from BSL to WK8), the rate constant of the changes in serum 25OHD per microgram of VitD<sub>3</sub> consumed (nmol/L/&#x000b5;g vitamin D<sub>3</sub>) was calculated for both Gr.Suppl.5 and Gr.Suppl.10 (secondary outcome). The rate constant measurement indicates to what extent added dietary vitamin D<sub>3</sub> raises the level of s25OHD compared to baseline. It represents the amount of VitD<sub>3</sub> biologically converted to 25OHD as assessed in serum samples at a specific time after the onset of the intervention. It is a quantitative estimate of the efficiency of the intervention. Over the first 8&#x000a0;weeks of the intervention, s25OHD virtually remained constant in Gr.Suppl.0 (see <xref ref-type="table" rid="t0001">Table&#x000a0;1</xref>). This avoided any substraction or addition computed from changes in the time control group.<table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Evolution of serum 25OHD in the 3 randomized groups<xref ref-type="fn" rid="t2fn0001"/>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="20pt" align="left"/><col width="20pt" align="left"/><col width="20pt" align="left"/><col width="20pt" align="left"/></colgroup><thead><tr><th align="left"><italic>n</italic></th><th align="center">Gr.Suppl.0</th><th align="center">Gr.Suppl.5</th><th align="center">Gr.Suppl.10</th></tr><tr><th align="center">&#x000a0;</th><th align="center">45</th><th align="center">44</th><th align="center">44</th></tr></thead><tbody><tr><td align="left">BSL</td><td align="char" char="(">36.4 (15.8)</td><td align="char" char="(">36.5 (14.6)</td><td align="char" char="(">35.9 (14.8)</td></tr><tr><td align="left">WK4</td><td align="char" char="(">31.8 (14.9)</td><td align="char" char="(">41.4 (11.7)</td><td align="center">44.5 (11.3)</td></tr><tr><td align="left">WK8</td><td align="char" char="(">36.6 (16.3)</td><td align="char" char="(">48.8 (12.7)</td><td align="char" char="(">54.3 (16.6)</td></tr><tr><td align="left">WK12</td><td align="char" char="(">38.7 (17.7)</td><td align="char" char="(">51.0 (16.3)</td><td align="char" char="(">55.4 (15.9)</td></tr><tr><td align="left">WK16</td><td align="char" char="(">44.1 (17.9)</td><td align="char" char="(">54.8 (15.9)</td><td align="char" char="(">59.4 (17.2)</td></tr><tr><td align="left">WK24</td><td align="char" char="(">49.5 (18.8)</td><td align="char" char="(">52.6 (17.0)</td><td align="char" char="(">58.9 (19.9)</td></tr></tbody></table><table-wrap-foot><fn><p>25OHD = 25-hydroyvitamin D, Gr.Suppl.0 = no vitamin D<sub>3</sub>&#x02013;fortified yogurt consumption; recommendation to maintain dietary habits during 24&#x000a0;weeks, Gr.Suppl.5 = 1 vitamin D<sub>3</sub>&#x02013;fortified yogurt/d during 16&#x000a0;weeks followed by 8&#x000a0;weeks without product, Gr.Suppl.10 = 2 vitamin D<sub>3</sub>&#x02013;fortified yogurts/d during 16&#x000a0;weeks followed by 8&#x000a0;weeks without product, BSL = baseline visit, WK4 to WK24 = number of weeks elapsed from the baseline visit, WK16 = end of the intervention for both Gr.Suppl.5 and Gr.Suppl.10, WK24 = 8&#x000a0;weeks after discontinuation of the intervention for both Gr.Suppl.5 and Gr.Suppl.10.</p></fn><fn id="t2fn0001"><label><sup>a</sup></label><p>Serum 25OHD values are means (SD) in nanomoles per liter. Probability levels for group-by-time interaction (repeated measures analysis of variance) for the evolution of serum 25OHD from BSL to WK16 were <italic>p</italic> = 0.0001 for the difference between Gr.Suppl.10 or Gr.Suppl.5 and Gr.Suppl.0 and <italic>p</italic> = 0.0417 for the difference between Gr.Suppl.10 and Gr.Suppl.5. Probability levels for the evolution following the discontinuation of the intervention&#x02014;that is from WK16 to WK24&#x02014;were <italic>p</italic> = 0.0025 and <italic>p</italic> = 0.0321 for the differences between Gr.Suppl.0&#x000a0;vs Gr.Suppl.5 and Gr.Suppl.10, respectively, and <italic>p</italic> = 0.706 for the difference between Gr.Suppl.10 and Gr.Suppl.5.</p></fn></table-wrap-foot></table-wrap>
</p><p>The influence of seasonality was assessed by dichotomizing the 3 randomized groups (Gr.Suppl.0, Gr.Suppl.5, and Gr.Suppl.10) as early (or winter set) and late (spring set) according to the date of enrollment (secondary outcome). The absolute values at BSL, WK4, WK8, and WK16 as well as changes from BSL to WK8 and to WK16 between early and late enrollment were compared by ANOVA for each of the 3 randomized experimental groups. Furthermore, the differences between the 3 groups from baseline to WK24 in the proportion of subjects displaying a serum 25OHD level &#x02265;50 nmol/L <xref rid="cit0004" ref-type="bibr">[4]</xref> were assessed by chi-square test. Statistical analyses were performed using SAS software, Version 9.3 (SAS Institute Inc., Cary, NC).</p></sec></sec><sec sec-type="results" id="s0003"><title>Results</title><sec id="s0003-0001"><title>Demographic characteristics at baseline</title><p>There were no significant differences between the 3 randomized groups in relation to either age or anthropometric variables (<xref ref-type="table" rid="t0001">Table&#x000a0;1</xref>).<table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Baseline demographic characteristics of the 3 randomized groups<xref ref-type="fn" rid="t1fn0001"/>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="20pt" align="left"/><col width="20pt" align="left"/><col width="20pt" align="left"/><col width="20pt" align="left"/></colgroup><thead><tr><th align="left"><italic>n</italic></th><th align="center">Gr.Suppl.0</th><th align="center">Gr.Suppl.5</th><th align="center">Gr.Suppl.10</th></tr><tr><th align="center">&#x000a0;</th><th align="center">45</th><th align="center">44</th><th align="center">44</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="char" char="(">62.6 (5.4)</td><td align="char" char="(">60.4 (4.0)</td><td align="char" char="(">61.4 (5.3)</td></tr><tr><td align="left">Weight (kg)</td><td align="char" char="(">65.1 (7.4)</td><td align="char" char="(">64.0 (9.3)</td><td align="char" char="(">63.9 (7.3)</td></tr><tr><td align="left">Height (cm)</td><td align="char" char="(">163.0 (5.4)</td><td align="char" char="(">161.5 (5.3)</td><td align="char" char="(">160.9 (6.0)</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td align="char" char="(">24.5 (2.7)</td><td align="char" char="(">24.5 (3.3)</td><td align="char" char="(">24.7 (2.7)</td></tr><tr><td align="left">Waist circumference (cm)</td><td align="char" char="(">86.8 (7.4)</td><td align="char" char="(">85.3 (9.3)</td><td align="char" char="(">85.9 (8.0)</td></tr></tbody></table><table-wrap-foot><fn><p>Gr.Suppl.0 = no vitamin D<sub>3</sub>&#x02013;fortified yogurt consumption; recommendation to maintain dietary habits during 24&#x000a0;weeks, Gr.Suppl.5 = 1 vitamin D<sub>3</sub>&#x02013;fortified yogurt/d during 16&#x000a0;weeks followed by 8&#x000a0;weeks without product, Gr.Suppl.10 = 2 vitamin D<sub>3</sub>&#x02013;fortified yogurts/d during 16&#x000a0;weeks followed by 8&#x000a0;weeks without product, BMI = body mass index.</p></fn><fn id="t1fn0001"><label><sup>a</sup></label><p>Values are means (SD). There was no statistically significant difference (overall analysis of variance) between the 3 groups for any of the 5 characteristics.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="s0003-0002"><title>s25OHD evolution</title><p>The evolution of s25OHD levels in the 133 participants during the 16-week intervention (BSL to WK16) and 8&#x000a0;weeks after discontinuation (WK24) is presented in <xref ref-type="table" rid="t0002">Table&#x000a0;2</xref>. The baseline level was quite similar (about 36&#x000a0;nmol/L) among the 3 randomized groups and was within the insufficiency range in conformance with one prespecified inclusion criterion. From BSL to WK8, there was a dose-related increase in s25OHD of 12.3 and 18.4&#x000a0;nmol/L in Gr.Suppl.5 and Gr.Suppl.10, respectively (<xref ref-type="table" rid="t0002">Table&#x000a0;2</xref> and <xref ref-type="fig" rid="f0001A">Figure&#x000a0;1A</xref>). From BSL to WK16, differences in changes were highly significant between Gr.Suppl.5 and Gr.Suppl.0 (18.3&#x000a0;vs 7.7&#x000a0;nmol/L, <italic>t</italic> test: <italic>p</italic> = 0.0007) and between Gr.Suppl.10 and Gr.Suppl.0 (23.5&#x000a0;vs 7.7&#x000a0;nmol/L, <italic>t</italic> test: <italic>p</italic> = 0.000001). The corresponding difference in change between Gr.Suppl.5 and Gr.Suppl.10 was not statistically significant (18.3&#x000a0;vs 23.5&#x000a0;nmol/L, <italic>y</italic> test: <italic>p</italic> = 0.116).<fig id="f0001A" orientation="portrait" position="float"><label>Figure 1A.</label><caption><p>Change (&#x02206;) in s25OHD in nanomoles per liter from baseline to weeks 4, 8, 12, and 16 after the onset of the intervention. One hundred thirty-three healthy menopausal women were randomized into 3 groups: Gr.Suppl.0, who were advised not to change their dietary habits; Gr.Suppl.5, who consumed one fortified yogurt that provided 5 &#x000b5;g of vitamin D<sub>3</sub> per day; and Gr.Suppl.10, who consumed 2 fortified yogurts that provided 10 &#x000b5;g of vitamin D<sub>3</sub> per day. The SD values are written in association with each column. Statistical test by repeated measures ANOVA indicates that the differences between Gr.Suppl.5 or Gr.Suppl.10 and Gr.Suppl.0 was significant at <italic>p</italic> = 0.0007 and <italic>p</italic> = 0.00002, respectively. The difference between Gr.Suppl.5 and Gr, Suppl.10 was not significant taking into account an adjustment for 3 comparisons reducing the <italic>p</italic> level from 0.050 to 0.0167.</p></caption><graphic content-type="black-white" xlink:href="UACN_A_1355761_F0001A_B"/></fig>
</p><p>After 8&#x000a0;weeks of yogurt consumption, serum 25OHD was increased to 89.1% (Gr.Suppl.5) and to 94.1% (Gr.Suppl.10) of the level measured after 16&#x000a0;weeks (<xref ref-type="table" rid="t0002">Table&#x000a0;2</xref>). In the control group (Gr.Suppl.0), during the first 8&#x000a0;weeks, s25OHD remained stable: 36.4 at BSL and 36.6 nmol/L at WK8 (<xref ref-type="table" rid="t0002">Table&#x000a0;2</xref>, <xref ref-type="fig" rid="f0001A">Figure&#x000a0;1A</xref>). Thereafter it rose significantly to reach a level of 44.1&#x000a0;nmol/L at week 16 (<xref ref-type="table" rid="t0002">Table&#x000a0;2</xref>, <xref ref-type="fig" rid="f0001A">Figure&#x000a0;1A</xref>). After discontinuation of the intervention, from WK16 to WK24, s25OHD was virtually maintained in both Gr.Suppl.10 (&#x02212;0.57 &#x000b1; 1.68&#x000a0;nmol/L, <italic>p</italic> = 0.738) and Gr.Suppl.5 (&#x02212;2.20 &#x000b1; 1.62&#x000a0;nmol/L, <italic>p</italic> = 0.182) and it significantly rose in Gr.Suppl.0 (+5.53 &#x000b1; 1.61, <italic>p</italic> = 0.0015; <xref ref-type="table" rid="t0002">Table&#x000a0;2</xref>). As indicated in <xref ref-type="table" rid="t0002">Table&#x000a0;2</xref>, the evolution from WK16 to WK24 was significantly different between the 2 groups who consumed VitD-fortified yogurts and the control group. At WK8, the proportion of subjects who achieved s25OHD levels &#x02265;50&#x000a0;nmol/L&#x02014;the threshold between insufficient and sufficient vitamin D status according to the 2011 Institute of Medicine report <xref rid="cit0004" ref-type="bibr">[4]</xref>&#x02014;was 22.2, 45.5, and 54.5% in Gr.Suppl.0, Gr.Suppl.5, and Gr.Suppl.10, respectively (<xref ref-type="fig" rid="f0002">Figure&#x000a0;1B</xref>). At WK16, the corresponding proportion was 37.8, 54.5, and 63.6%, respectively (<xref ref-type="fig" rid="f0002">Figure&#x000a0;1B</xref>).<fig id="f0001B" orientation="portrait" position="float"><label>Figure 1B.</label><caption><p>Proportion of subjects whose s25OHD increased to &#x02265;50&#x000a0;nmol/L from baseline to the end of the intervention (WK16) and 8&#x000a0;weeks later (WK24). The figure illustrates a dose effect related to the duration of the intervention from BSL to WK16. The seasonality effect is highlighted by the increase in the time-controlled group (Gr.Suppl.0) from BSL (samples collected on average from mid-January to mid-March 2015) to WK24 (samples collected on average from mid-July to mid-August 2015). The corresponding absolute values (mean &#x000b1; SD) of s25OHD in nanomoles per liter are presented in <xref ref-type="fig" rid="f0001A">Figure&#x000a0;1A</xref>. The probability of difference as assessed by chi-squared tests was <italic>p</italic> = 0.002 and <italic>p</italic> = 0.088 between Gr.Suppl.0 and Gr.Suppl.5 at WK8 and WK16, respectively, and <italic>p</italic> = 0.0001 and <italic>p</italic> = 0.008 between Gr.Suppl.0 and Gr.Suppl.10 at WK8 and WK16, respectively. At WK24, there was a trend (<italic>p</italic> = 0.081) for a greater proportion of participants maintaining an s25OHD level &#x02265;50 nmol/L in Gr.Suppl.10 (29/44 = 65.9%) than in Gr.Suppl.5 (21/44 = 47.7%).</p></caption><graphic content-type="black-white" xlink:href="UACN_A_1355761_F0001B_B"/></fig>
</p></sec><sec id="s0003-0003"><title>s25OHD response in relation to baseline level</title><p>Based on screening s25OHD levels, the participants were segregated into low stratum (LowStr from 25 to 50&#x000a0;nmol/L, <italic>n</italic> = 53) and high stratum (HighStr &#x02265; 50&#x000a0;to 75&#x000a0;nmol/L, <italic>n</italic> = 80). The evolution from BSL to WK24 of the absolute s25OHD values indicates a dose effect of VitD<sub>3</sub>-fortified yogurts in both LowStr and HighStr subgroups (<xref ref-type="table" rid="t0003">Table&#x000a0;3</xref>). The changes from baseline to 8&#x000a0;weeks were as follows: for Gr.Suppl.5: 17.4&#x000a0;nmol/L LowStr vs 8.4&#x000a0;nmol/L HighStr (<xref ref-type="fig" rid="f0003">Figure&#x000a0;2</xref>); for Gr.Suppl.10: 27.1&#x000a0;nmol/L LowStr vs 13.5&#x000a0;nmol/L HighStr; for Gr.Suppl.0: 3.0&#x000a0;nmol/L LowStr vs &#x02212;1.6&#x000a0;nmol/mL HighStr (<xref ref-type="fig" rid="f0003">Figure&#x000a0;2</xref>). Thus, the absolute increase in s25OHD after 8&#x000a0;weeks was greater in LowStr than in HighStr regardless of the daily vitamin D<sub>3</sub> amounts consumed (5 or 10 &#x000b5;g).<table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Evolution of serum 25OHD in subjects distributed according to their initial vitamin D status<xref ref-type="fn" rid="t3fn0001"/>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="20pt" align="left"/><col width="20pt" align="left"/><col width="20pt" align="left"/><col width="20pt" align="left"/><col width="20pt" align="left"/><col width="20pt" align="left"/><col width="20pt" align="left"/></colgroup><thead><tr><th align="left">&#x000a0;</th><th colspan="2" align="center">Gr.Suppl.0<hr/></th><th colspan="2" align="center">Gr.Suppl.5<hr/></th><th colspan="2" align="center">Gr.Suppl.10<hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="center">Low Stratum</th><th align="center">High Stratum</th><th align="left">Low Stratum</th><th align="left">High Stratum</th><th align="left">Low Stratum</th><th align="left">High Stratum</th></tr></thead><tbody><tr><td align="left"><italic>n</italic><hr/></td><td align="center">18<hr/></td><td align="center">27<hr/></td><td align="center">19<hr/></td><td align="center">25<hr/></td><td align="center">16<hr/></td><td align="center">28<hr/></td></tr><tr><td align="left">BSL</td><td align="char" char="(">22.0 (7.4)</td><td align="char" char="(">46.0 (12.1)</td><td align="char" char="(">26.8 (10.4)</td><td align="char" char="(">43.9 (13.0)</td><td align="char" char="(">23.0 (8.5)</td><td align="char" char="(">43.2 (12.5)</td></tr><tr><td align="left">WK4</td><td align="char" char="(">19.2 (8.8)</td><td align="char" char="(">40.1 (12.0)</td><td align="char" char="(">35.3 (9.4)</td><td align="char" char="(">46.1 (11.3)</td><td align="char" char="(">38.2 (10.0)</td><td align="char" char="(">48.1 (10.5)</td></tr><tr><td align="left">WK8</td><td align="char" char="(">24.9 (10.5)</td><td align="char" char="(">44.4 (14.9)</td><td align="char" char="(">44.2 (11.1)</td><td align="char" char="(">52.3 (12.9)</td><td align="char" char="(">50.1 (16.7)</td><td align="char" char="(">56.7 (16.3)</td></tr><tr><td align="left">WK12</td><td align="char" char="(">27.7 (13.0)</td><td align="char" char="(">46.1 (16.8)</td><td align="char" char="(">45.3 (12.3)</td><td align="char" char="(">55.3 (17.8)</td><td align="char" char="(">51.6 (15.2)</td><td align="char" char="(">57.5 (16.1)</td></tr><tr><td align="left">WK16</td><td align="char" char="(">33.8 (16.2)</td><td align="char" char="(">51.0 (15.8)</td><td align="char" char="(">50.2 (13.3)</td><td align="char" char="(">58.4 (17.1)</td><td align="char" char="(">54.0 (17.5)</td><td align="char" char="(">62.5 (16.5)</td></tr><tr><td align="left">WK24</td><td align="char" char="(">37.9 (14.1)</td><td align="char" char="(">57.2 (17.7)</td><td align="char" char="(">46.0 (13.5)</td><td align="char" char="(">57.7 (17.9)</td><td align="char" char="(">50.8 (14.9)</td><td align="char" char="(">63.5 (21.1)</td></tr></tbody></table><table-wrap-foot><fn><p>25OHD = 25-hydroyvitamin D, Gr.Suppl.0 = no vitamin D<sub>3</sub>&#x02013;fortified yogurt consumption; recommendation to maintain dietary habits during 24&#x000a0;weeks, Gr.Suppl.5 = 1 vitamin D<sub>3</sub>&#x02013;fortified yogurt/d during 16&#x000a0;weeks followed by 8&#x000a0;weeks without product, Gr.Suppl.10 = 2 vitamin D<sub>3</sub>&#x02013;fortified yogurts/d during 16&#x000a0;weeks followed by 8&#x000a0;weeks without product, BSL = baseline visit, WK4 toWK24 = number of weeks elapsed from the baseline visit, WK16 = end of the intervention for both Gr.Suppl.5 and Gr.Suppl.10, WK24 = 8&#x000a0;weeks after discontinuation of the intervention for both Gr.Suppl.5 and Gr.Suppl.10.</p></fn><fn id="t3fn0001"><label><sup>a</sup></label><p>Serum 25OHD values are means (SD) in nanomoles per liter. The participants were distributed as low or high according to their serum 25OHD screening values; that is, before the BSL visit. Low stratum range: 25 to 50&#x000a0;nmol/L; high stratum range: &#x02265;50 to 75&#x000a0;nmol/L. Probability levels for group-by-time interaction (repeated measures analysis of variance) for the evolution of serum 25OHD from BSL to WK16 were as follows: low stratum: <italic>p</italic> = 0.0001 and <italic>p</italic> = 0.0012 for the difference between Gr.Suppl.10 or Gr.Suppl.5 and Gr.Suppl.0, respectively, and <italic>p</italic> = 0.0346 for the difference between Gr.Suppl.10 and Gr.Suppl.5.</p></fn></table-wrap-foot></table-wrap>
<fig id="f0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Change (&#x02206;) in s25OHD in nanomoles per liter from baseline to weeks 4, 8, 12, and 16 after the onset of the intervention. One hundred thirty-three healthy menopausal women were randomized into 3 groups: Gr.Suppl.0, who were advised not to change their dietary habits; Gr.Suppl.5, who consumed one fortified yogurt providing 5 &#x000b5;g of vitamin D<sub>3</sub> per day; and Gr.Suppl.10, who consumed 2 fortified yogurts providing 10 &#x000b5;g of vitamin D<sub>3</sub> per day. Based on s25OHD values measured in screening samples, the cohort was divided into 2 strata: low, from 25 to 50&#x000a0;nmol/L, and high, from &#x0003e;50 to 75&#x000a0;nmol/L. The statistical significance by repeated measures ANOVA indicates that the differences between Gr.Suppl.5 or Gr.Suppl.10 and Gr.Suppl.0 for the low stratum were significant at <italic>p</italic> = 0.0012 and <italic>p</italic> = 0.0001, respectively. For the high stratum, the corresponding significance was <italic>p</italic> = 0.0020 and <italic>p</italic> = 0.0001, respectively. The difference between Gr.Suppl.5 and Gr.Suppl.10 was significant in the low stratum (<italic>p</italic> = 0.0346) but not in the high stratum (<italic>p</italic> = 0.416). The influence of baseline serum 25OHD level on the progressive increase in serum 25OHD during the intervention was significantly greater in the low stratum than in the high stratum (<italic>p</italic> = 0.0001).</p></caption><graphic content-type="black-white" xlink:href="UACN_A_1355761_F0002_B"/></fig>
</p></sec><sec id="s0003-0004"><title>s25OHD rate constant</title><p>The rate constant was calculated based on the increase in s25OHD per microgram of VitD<sub>3</sub> consumed from BSL to WK8. For all participants in the 2 vitamin D<sub>3</sub>&#x02013;supplemented groups, it was not significantly different between Gr.Suppl.5 and Gr.Suppl.10 (1.49&#x000a0;vs 1.18&#x000a0;nmol/L, respectively; <xref ref-type="fig" rid="f0004">Figure&#x000a0;3</xref>). By comparing the 2 strata according to baseline s25OHD, it was 2.3- and 2.9-fold greater in LowStr than in HighStr in Gr.Suppl.5 and Gr.Suppl.10, respectively (<xref ref-type="fig" rid="f0004">Figure&#x000a0;3</xref>).<fig id="f0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Changes in s25OHD during the first 8 weeks following the consumption of 1 or 2 vitamin D<sub>3</sub>&#x02013;fortified yogurts that increased the intake of vitamin D<sub>3</sub> up to 5 and 10 &#x000b5;g per day, respectively. Columns indicate the rate constant of the increase in s25OHD in nanomoles per liter per 1 &#x000b5;g of supplemental vitamin D<sub>3</sub>. SD values are written in association with each column. The totality (ALL) of participants (left 2 columns) was separated into a high stratum (middle 2 columns) and low stratum (right 2 columns) according to the values of s25OHD as measured in screening samples: &#x0003e;50 to 75 and 25 to &#x02264;50 nmol/L, respectively. Number of subjects: ALL, 44 and 44 in Gr.Suppl.5 and Gr.Suppl.10, respectively; high stratum, 25 and 28; low stratum, 19 and 16 in Gr.Suppl.5 and Gr.Suppl.10, respectively. Statistical evaluation by ANOVA between Gr.Suppl.5 and Gr.Suppl.10: ALL, <italic>p</italic> = 0.488; high stratum, <italic>p</italic> = 0.452; low stratum, <italic>p</italic> = 0.794. Difference between high stratum and low stratum: <italic>p</italic> = 0.0006.</p></caption><graphic content-type="black-white" xlink:href="UACN_A_1355761_F0003_B"/></fig>
</p></sec><sec id="s0003-0005"><title>Seasonal effect on s25OHD</title><p>The 133 participants were enrolled between early January and late April 2015. In order to assess whether s25OHD was influenced by enrollment time, we analyzed the evolution of vitamin D status after dichotomization of the 3 investigated groups as early (BSL in January) and late (BSL in March) enrollment (<xref ref-type="table" rid="t0004">Table&#x000a0;4</xref>). At BSL, in each randomized group there was no significant difference in s25OHD between early and late enrollment (<xref ref-type="table" rid="t0004">Table&#x000a0;4</xref>). Mean s25OHD changes measured in the parallel time-controlled group illustrate the influence of enrollment time (as designated by the term <italic>seasonality</italic>) in the absence of any VitD<sub>3</sub> supplementation. In Gr.Suppl.0, the increase in s25OHD from BSL to WK16 was +1.1 nmol/L in the early group and +14.1&#x000a0;nmol/L in the late group. In Gr.Suppl.5, the corresponding increase was +15.2&#x000a0;nmol/L in the early group and +21.4&#x000a0;nmol/L in the late group. In Gr.Suppl.10, it was +12.5&#x000a0;nmol/L in the early group and +24.5&#x000a0;nmol/L in the late group (<xref ref-type="table" rid="t0004">Table&#x000a0;4</xref> and <xref ref-type="fig" rid="f0004">Figure&#x000a0;4</xref>). The contribution of the seasonality effect to the changes measured in the 2 groups consuming VitD<sub>3</sub>-fortified yogurts from BSL to WK16 may be roughly estimated by subtracting the corresponding change assessed in Gr.Suppl.0 (<xref ref-type="table" rid="t0004">Table&#x000a0;4</xref> and <xref ref-type="fig" rid="f0004">Figure&#x000a0;4</xref>).<table-wrap id="t0004" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Influence of sampling date on serum 25OHD evolution in healthy menopausal women supplemented with vitamin D<sub>3</sub> at 5 (Gr.Suppl.5) or 10 &#x000b5;g/d (Gr.Suppl.10) Compared to Time-Controlled Nonsupplemented Participants (Gr.Suppl.0)<xref ref-type="fn" rid="t4fn0001"/>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="20pt" align="left"/><col width="20pt" align="left"/><col width="20pt" align="left"/><col width="20pt" align="left"/><col width="20pt" align="left"/><col width="20pt" align="left"/><col width="20pt" align="left"/><col width="20pt" align="left"/><col width="20pt" align="left"/><col width="20pt" align="left"/></colgroup><thead><tr><th align="left">&#x000a0;</th><th colspan="2" align="center">Gr.Suppl.0<hr/></th><th colspan="2" align="center">Gr.Suppl.5<hr/></th><th colspan="2" align="center">Gr.Suppl.10<hr/></th><th align="center">&#x000a0;</th><th align="center">&#x000a0;</th><th align="center">&#x000a0;</th></tr><tr><th align="left"><italic>n</italic></th><th align="center">22</th><th align="center">23</th><th align="center">22</th><th align="center">22</th><th align="center">22</th><th align="center">22</th><th align="center">&#x000a0;</th><th align="center">&#x000a0;</th><th align="center">&#x000a0;</th></tr><tr><th align="left">Sampling Time</th><th align="center">Early</th><th align="center">Late</th><th align="center">Early</th><th align="center">Late</th><th align="center">Early</th><th align="center">Late</th><th align="center"><italic>p.0</italic></th><th align="center"><italic>p.5</italic></th><th align="center"><italic>p.10</italic></th></tr></thead><tbody><tr><td align="left">Date value BSL: Range</td><td align="center">42010-42039</td><td align="center">42044-42116</td><td align="center">42010-42044</td><td align="center">42044-42116</td><td align="center">42010-42044</td><td align="center">42046-42116</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x02003;Date value BSL: Mean</td><td align="center">42020</td><td align="center">42076</td><td align="center">42021</td><td align="center">42080</td><td align="center">42022</td><td align="center">42080</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x02003;Mean Date BSL: M/D/Y</td><td align="center">01/16/2015</td><td align="center">03/13/2015</td><td align="center">01/17/2015</td><td align="center">03/17/2015</td><td align="center">01/18/2015</td><td align="center">03/17/2015</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x02003;25OHD BSL</td><td align="center">35.1 (14.2)</td><td align="center">37.6 (17.5)</td><td align="center">36.8 (14.2)</td><td align="center">36.3 (15.3)</td><td align="center">38.1 (15.2)</td><td align="center">33.6 (14.5)</td><td align="center">0.612</td><td align="center">0.902</td><td align="center">0.316</td></tr><tr><td align="left">Date value WK8: Range</td><td align="center">42066-42095</td><td align="center">42100-42172</td><td align="center">42066-42102</td><td align="center">42101-42172</td><td align="center">42066-42101</td><td align="center">42102-42172</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x02003;Date value WK8: Mean</td><td align="center">42076</td><td align="center">42132</td><td align="center">42077</td><td align="center">42136</td><td align="center">42078</td><td align="center">42136</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x02003;Mean Date WK8: M/D/Y</td><td align="center">03/13/2015</td><td align="center">05/08/2015</td><td align="center">03/14/2015</td><td align="center">05/12/2015</td><td align="center">03/15/2015</td><td align="center">05/12/2015</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x02003;25OHD WK8 </td><td align="center">31.6 (13.6)</td><td align="center">41.5 (17.6)</td><td align="center">48.4 (11.0)</td><td align="center">49.1 (14.5)</td><td align="center">50.6 (13.9)</td><td align="center">58.1 (18.4)</td><td align="center">0.041</td><td align="center">0.383</td><td align="center">0.136</td></tr><tr><td align="left">Date value WK16: Range</td><td align="center">42122-42151</td><td align="center">42156-42228</td><td align="center">42122-42156</td><td align="center">42156-4228</td><td align="center">42122-42226</td><td align="center">42156-42233</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x02003;Date value WK16: Mean</td><td align="center">42132</td><td align="center">42188</td><td align="center">42133</td><td align="center">42192</td><td align="center">42136</td><td align="center">42186</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x02003;Mean Date WK16: M/D/Y</td><td align="center">05/08/2015</td><td align="center">07/03/2015</td><td align="center">05/09/2015</td><td align="center">07/07/2015</td><td align="center">05/12/2013</td><td align="center">07/01/2015</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x02003;25OHD WK16</td><td align="center">36.2 (13.4)</td><td align="center">51.6 (18.7)</td><td align="center">52.0 (14.2)</td><td align="center">57.7 (17.4)</td><td align="center">54.2 (14.1)</td><td align="center">64.6 (18.7)</td><td align="center">0.003</td><td align="center">0.238</td><td align="center">0.042</td></tr><tr><td align="left">Date value WK24:Range</td><td align="center">42174-42207</td><td align="center">42212-42284</td><td align="center">42178-42212</td><td align="center">42212-42285</td><td align="center">42172-42212</td><td align="center">42209-42284</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x02003;Date value WK24:Mean</td><td align="center">42188</td><td align="center">42243</td><td align="center">42190</td><td align="center">42248</td><td align="center">42190</td><td align="center">42248</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x02003;Mean Date WK24: M/D/Y</td><td align="center">07/03/2015</td><td align="center">08/27/2015</td><td align="center">07/05/2015</td><td align="center">09/01/2015</td><td align="center">07/05/2015</td><td align="center">09/01/2015</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr><tr><td align="left">&#x02003;25OHD WK24 </td><td align="center">42.9 (15.5)</td><td align="center">55.8 (19.9)</td><td align="center">49.4 (13.3)</td><td align="center">55.9 (19.9)</td><td align="center">50.7 (15.1)</td><td align="center">67.0 (21.1)</td><td align="center">0.019</td><td align="center">0.205</td><td align="center">0.005</td></tr></tbody></table><table-wrap-foot><fn><p>25OHD = 25-hydroyvitamin D, Gr.Suppl.0 = no vitamin D<sub>3</sub>&#x02013;fortified yogurt consumption; recommendation to maintain dietary habits during 24&#x000a0;weeks, Gr.Suppl.5 = 1 vitamin D<sub>3</sub>&#x02013;fortified yogurt/d during 16&#x000a0;weeks followed by 8&#x000a0;weeks without product, Gr.Suppl.10 = 2 vitamin D<sub>3</sub>&#x02013;fortified yogurts/d during 16&#x000a0;weeks followed by 8&#x000a0;weeks without product, BSL = baseline visit, WK4 toWK24 = number of weeks elapsed from the baseline visit, WK16 = end of the intervention for both Gr.Suppl.5 and Gr.Suppl.10, WK24 = 8&#x000a0;weeks after discontinuation of the intervention for both Gr.Suppl.5 and Gr.Suppl.10.</p></fn><fn id="t4fn0001"><label><sup>a</sup></label><p>Serum 25OHD values are means (SD) in nanomoles per liter. Date value = Date stored as text in month/day/year (M/D/Y) converted into a serial number, 1 = 01/01/1900. The participants were divided as early or late according to their serum 25OHD sampling dates at baseline (BSL). The next measurements were made after 8 and 16&#x000a0;weeks of intervention and 8&#x000a0;weeks after discontinuation of intervention (WK24). <italic>p</italic>.0, <italic>p</italic>.5, <italic>p</italic>.10: Probability level in serum 25OHD differences between early and late samplings for Gr.Suppl.0, Gr.Suppl.5, and Gr.Suppl.10, respectively.</p></fn></table-wrap-foot></table-wrap>
<fig id="f0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Changes in s25OHD after 8 and 16&#x000a0;weeks of intervention. The 3 randomized groups were divided into 2 subgroups according to enrollment date: early (January 16&#x02013;18, 2015) and late (March 13&#x02013;17, 2015). The figure illustrates the interactions between the sampling date (season effect) and the amount of vitamin D<sub>3</sub> (dose effect) as consumed from fortified yogurt that provided daily either 5 &#x000b5;g (Gr.Suppl.5) or 10 &#x000b5;g (Gr.Suppl.10) compared to a time-controlled group (Gr.Suppl.0). The SD values are written in association with each column. See <xref ref-type="table" rid="t0004">Table&#x000a0;4</xref> for the corresponding absolute values, the number of subjects in each subgroup, as well as the probability level for the differences in s250HD between early and late for Gr.Suppl.0, Gr.Suppl.5, and Gr.Suppl.10.</p></caption><graphic content-type="black-white" xlink:href="UACN_A_1355761_F0004_B"/></fig>
</p></sec><sec id="s0003-0006"><title>Evolution of anthropometric, cardiovascular variables, and serum calcium</title><p>Over the 16&#x000a0;weeks of intervention, no significant change was observed in body weight, BMI, and waist circumference. Measurements of diastolic/systolic blood pressure remained stable in the 3 groups from BSL to WK8 and WK16. Likewise, serum calcium was not modified by the intervention.</p></sec><sec id="s0003-0007"><title>Adherence to consumption of vitamin D3&#x02013;supplemented yogurts</title><p>The degree of adherence as assessed by the number of yogurt pot lids returned by the participants at each visit compared to the number of theoretical number of yogurts distributed remained quite stable from WK4 to WK16, varying from 93% to 100% and from 82% to 100% in Gr.Suppl.5 and Gr.Suppl.10, respectively (<italic>p</italic> = 0.084).</p></sec><sec id="s0003-0008"><title>Acceptability</title><p>The tested products, whether consumed at a daily rate of 1 or 2 fortified yogurts, were well accepted in terms of taste, with no negative feeling concerning the dairy product size, a factor that may reduce appetite and thereby limit food intake.</p></sec></sec><sec sec-type="discussion" id="s0004"><title>Discussion</title><sec id="s0004-0001"><title>Main results</title><p>This article highlights the relative importance of 3 interdependent determinants of the response to VitD<sub>3</sub>-fortified foods documented in one single randomized clinical trial carried out in menopausal women. It provides information on the impact of VitD<sub>3</sub>-fortified yogurt taken at 2 dose levels compared to a time-controlled group and on the quantitative influence of the baseline vitamin D status. It emphasizes the distinct impact of 2 amounts of VitD<sub>3</sub> consumed orally in relation to the period of the year during which the intervention was conducted.</p></sec><sec id="s0004-0002"><title>Relation to supplemental doses</title><p>According to a 2011 report from the Institute of Medicine, a s25OHD level of &#x02265;50&#x000a0;nmol/L meets the needs, primarily related to bone health outcomes <xref rid="cit0004" ref-type="bibr">[4]</xref>, of at least 97.5% of the population. In our study, the baseline s25OHD value of approximately 36&#x000a0;nmol/L (<xref ref-type="fig" rid="f0001A">Figures 1A</xref> and 1B, <xref ref-type="table" rid="t0001">Table&#x000a0;1</xref>) fell within the insufficiency range. Following consumption of the VitD<sub>3</sub>-fortified yogurts, s25OHD crossed the sufficiency threshold of 50&#x000a0;nmol/L earlier with a dose of 10 &#x000b5;g/d (54.3&#x000a0;nmol/L after 8&#x000a0;weeks) and later with a dose of 5 &#x000b5;g/d (54.8&#x000a0;nmol/L after 16&#x000a0;weeks; <xref ref-type="table" rid="t0001">Table&#x000a0;1</xref>). Thus, the s25OHD kinetic response differentiates the 2 tested amounts of VitD<sub>3</sub> better than the absolute level attained by the end of the intervention (59.4&#x000a0;vs 54.8&#x000a0;nmol/L with 10&#x000a0;vs 5 &#x000b5;g/d after 16&#x000a0;weeks of intervention, <italic>p</italic> = 0.198; <xref ref-type="table" rid="t0002">Table&#x000a0;2</xref>).</p></sec><sec id="s0004-0003"><title>Relation to initial s25OHD level</title><p>Previous reports suggested an inverse correlation between baseline vitamin D status and an increase in s25OHD in response to either pharmaceutical supplement or food fortification <xref rid="cit0005" ref-type="bibr">[5,29,30]</xref>. The design of our randomized controlled study was prespecified to test this possible relationship. Our results clearly establish that the lower the baseline vitamin D status, the higher the absolute increment in s25OHD (<xref ref-type="fig" rid="f0003">Figure&#x000a0;2</xref>). The reasons for this inverse relationship remain conjectural. Among possible mechanisms are (1) the vitamin D status could influence the distribution of s25OHD; (2) the hepatic hydroxylation rate of the cholecalciferol molecule in position 25 could be inversely related to its product; (3) the affinity of the vitamin D binding protein(s) could vary according to vitamin D status; (4) the activity/induction of catabolic vitamin D 24-hydroxylase enzyme may be reduced in response to a prolonged decrease in the level of serum 25OHD <xref rid="cit0031" ref-type="bibr">[31&#x02013;33]</xref>.</p></sec><sec id="s0004-0004"><title>Rate constant of s25OHD increase or vitamin D<sub>3</sub> supplementation efficiency</title><p>The concept of rate constant as detailed by Heaney et&#x000a0;al. <xref rid="cit0018" ref-type="bibr">[18]</xref> is a useful link between the amount of vitamin D consumed as a supplement or fortified foods and improvement in vitamin D status. This value corresponds to an efficiency estimate of the supplemental VitD<sub>3</sub> consumed <xref rid="cit0018" ref-type="bibr">[18]</xref>. In a recent systematic review, the rate constant of change in s25OHD expressed as nanomoles per liter per microgram of additional vitamin D was calculated from 18 randomized controlled trials <xref rid="cit0005" ref-type="bibr">[5]</xref>. The mean rate constant close to 2.0&#x000a0;nmol/L per &#x000b5;g of vitamin D <xref rid="cit0005" ref-type="bibr">[5]</xref> was in agreement with an analysis of 41 studies with an average rate constant of 2.1 <xref rid="cit0034" ref-type="bibr">[34]</xref>. We observed an important effect of baseline s25OHD on the response to VitD<sub>3</sub>-fortified dairy. It was more than twice as high in the participants randomized as LowStr (25 to 50&#x000a0;nmol/L) compared to HighStr (&#x0003e;50 to 75&#x000a0;nmol/L; <xref ref-type="fig" rid="f0004">Figure&#x000a0;3</xref>).</p></sec><sec id="s0004-0005"><title>Dose&#x02013;response and seasonality</title><p>The magnitude of the effect of vitamin D consumption on its status should reflect both the supplemental dose as well as the season-related evolution of s25OHD. Our study ran from January to October and allows one to identify the relative importance of these 2 factors. Thus, the increase in response to VitD<sub>3</sub>-fortified yogurts would be substantially overestimated if one did not take into account the evolution of s25OHD as assessed in our study by monitoring a parallel time-control group. The difference between the control and the 2 supplemental groups decreased from the onset of the intervention to the end (<xref ref-type="table" rid="t0001">Table&#x000a0;1</xref> and <xref ref-type="fig" rid="f0001A">Figures 1A</xref> and 1B). Most likely, this attenuation of the fortified food effect results from the increased cutaneous production of VitD<sub>3</sub>. In the control group, s25OHD significantly increased from 36.4 to 44.1&#x000a0;nmol/L (+21.2%) from BSL (mean sampling time mid-February) to WK16 (mean sampling time early June). It increased further to 49.5&#x000a0;nmol/L 8&#x000a0;weeks later (WK24; mean sampling time early August). Thus, from February to August, without evidence of an increase in the food intake of vitamin D in the control group, the status evolved from insufficiency to reach the lower range of sufficiency (50&#x000a0;nmol/L) according to the 2011 Institute of Medicine report <xref rid="cit0004" ref-type="bibr">[4]</xref>. This evolution is in keeping with the influence of seasonality on vitamin D status, as studied in some European countries and the United States <xref rid="cit0011" ref-type="bibr">[11&#x02013;14,35]</xref>. The seasonality effect from 36.4 to 49.5&#x000a0;nmol/L in the control group (<xref ref-type="table" rid="t0001">Table&#x000a0;1</xref>) approximately equals the consumption during 8&#x000a0;weeks of fortified dairy providing 5 &#x000b5;g/d of supplemental VitD<sub>3</sub>, which increased the s25OHD level from 36.5 to 48.8&#x000a0;nmol/L (<xref ref-type="table" rid="t0001">Table&#x000a0;1</xref>). Nevertheless, it is somewhat less than that achieved during the same period, from 35.9 to 54.3&#x000a0;nmol/L, with 10 &#x000b5;g/d of supplemental VitD<sub>3</sub> (<xref ref-type="table" rid="t0001">Table&#x000a0;1</xref>). These results corroborate the utility of consuming supplemental vitamin D during the winter season.</p></sec><sec id="s0004-0006"><title>Food fortification for preventing vitamin D insufficiency in the general population</title><p>All enrolled subjects remained compliant with the prescribed fortified dairy products, whether consumed as 1 or 2 servings per day during 16&#x000a0;weeks. This high adherence should reflect the good acceptability of supplemental VitD<sub>3</sub> as provided through the consumption of fortified dairy products (for a review, see Whiting et&#x000a0;al. <xref rid="cit0036" ref-type="bibr">[36]</xref>).</p><p>In terms of public health programs aimed at preventing vitamin D insufficiency, adherence and acceptability are important criteria for achieving a beneficial effect of long-term supplementation. Relatively low vitamin D doses regularly consumed with usual foods offer some advantage over pharmaceutical pills that are either taken daily in small doses but with the risk of low compliance due to medication-related side effects <xref rid="cit0037" ref-type="bibr">[37]</xref> or, alternatively, taken in large amounts at monthly or yearly intervals with the nonnegligible risk of the occurrence of adverse events <xref rid="cit0038" ref-type="bibr">[38]</xref>.</p><p>The results of our randomized trial in healthy menopausal women pertain to the prevention of insufficient vitamin D status in the general population. Quantitatively, the presented evolution of s25OHD can be interpreted in relation to the 2011 Institute of Medicine report that established that a s25OHD level of at least 50&#x000a0;nmol/L meets the skeletal health requirements for vitamin D of &#x02265;97.5% of the general population <xref rid="cit0004" ref-type="bibr">[4]</xref>. Whether the benefits of vitamin D supplementation would only become manifest when s25OHD reaches a level of at least 75&#x000a0;nmol/L is controversial <xref rid="cit0003" ref-type="bibr">[3,39]</xref>. Furthermore, it remains uncertain that such a high level might be required for the adequate management of disease-related conditions such as cardiovascular disease, site-specific cancers, diabetes, chronic kidney disease, hepatic failure, malabsorption syndromes, and obesity <xref rid="cit0004" ref-type="bibr">[4,39]</xref>. In these pathological conditions, dairy and/or non-dairy food fortification with vitamin D <xref rid="cit0040" ref-type="bibr">[40]</xref> may not be enough to achieve a s25OHD level of 75&#x000a0;nmol/L and above, particularly when ultraviolet B radiation is limited, as recommended to the participants in our trial. To achieve such high levels, the use of vitamin D pharmaceutical supplements in amounts close to the estimated tolerable upper intake level, set at 100 &#x000b5;g/day <xref rid="cit0004" ref-type="bibr">[4]</xref>, appears appropriate.</p><p>Several epidemiological studies have shown an inverse association between s25OHD and age-adjusted mortality <xref rid="cit0041" ref-type="bibr">[41&#x02013;43]</xref>. This association between vitamin D status and mortality appears to be stronger with cardiovascular disease (CVD) than non-CVD pathologies <xref rid="cit0041" ref-type="bibr">[41]</xref>. A doubling of s25OHD between 40 and 90 nmol/L was associated with a 20% lower vascular mortality <xref rid="cit0044" ref-type="bibr">[44]</xref>. In 2 recent reports on a well-conducted randomized placebo-controlled trial entitled BEST-D trial (Biochemical Efficacy and Safety Trial of Vitamin D), the effects of daily supplementation of 2000 IU (50 &#x000b5;g) and 4000 IU (100 &#x000b5;g) for 1&#x000a0;year were assessed in about 300 community-dwelling people aged &#x02265;65&#x000a0;years in Oxfordshire <xref rid="cit0045" ref-type="bibr">[45,46]</xref>. s25OHD increased from a mean baseline level of 50&#x000a0;nmol/L to 102 and 137&#x000a0;nmol/L in those allocated daily VitD<sub>3</sub> doses of 50 and 100 &#x000b5;g, respectively <xref rid="cit0046" ref-type="bibr">[46]</xref>, whereas it barely changed in the placebo group. The authors concluded that 100 &#x000b5;g of VitD<sub>3</sub> may be required to achieve a lowest risk of CVD and other diseases such as certain types of cancer <xref rid="cit0046" ref-type="bibr">[46]</xref>. Of note, supplementation with these high doses of VitD<sub>3</sub> had no detectable effects on cardiovascular risk factors, including blood pressure, arterial stiffness, circulating lipids, and markers of inflammation <xref rid="cit0046" ref-type="bibr">[46]</xref>. Nevertheless, this randomized controlled trial cannot exclude benefits of CVD prevention beyond 1&#x000a0;year of treatment with high doses of VitD<sub>3</sub>.</p></sec><sec id="s0004-0007"><title>Strengths and weaknesses</title><p>This study has a number of strengths: <list list-type="simple"><list-item><label>1.</label><p>It provides information from a randomized controlled trial on the interaction of 3 important determinants of the vitamin D status prospectively studied in 133 menopausal women who remained adherent over the 24&#x000a0;weeks of the investigation.</p></list-item><list-item><label>2.</label><p>The kinetic analysis of the initial 8-week increment in s25OHD in response to the consumption of VitD<sub>3</sub>-fortified dairy clearly differentiates the 2 daily doses tested, namely, 5&#x000a0;vs 10 &#x000b5;g.</p></list-item><list-item><label>3.</label><p>The study also shows the attenuation of the difference between the 2 doses of supplemental VitD<sub>3</sub> during the 16&#x000a0;weeks of intervention.</p></list-item><list-item><label>4.</label><p>It furthermore unequivocally documents the inverse relationship between baseline vitamin D status and the response to VitD<sub>3</sub>-fortified yogurt.</p></list-item><list-item><label>5.</label><p>It demonstrates the marked interaction between the effect of VitD<sub>3</sub> supplementation and the season-dependent onset of the intervention.</p></list-item><list-item><label>6.</label><p>The study highlights the importance of VitD<sub>3</sub> supplementation during the winter season, even in amounts as low as 5 &#x000b5;g/d.</p></list-item><list-item><label>7.</label><p>Its practical utility in terms of public health, allowing a definition of the efficacious amount of VitD<sub>3</sub>-fortified foods to be consumed by menopausal women according to the season of the year in order to avoid the risk of vitamin D insufficiency.</p></list-item></list>
</p><p>Weaknesses include the following:<list list-type="simple"><list-item><label>1.</label><p>The absence of a placebo-control group that consumed the same dairy product without any VitD<sub>3</sub> fortification.</p></list-item><list-item><label>2.</label><p>An estimate by self-questionnaires of vitamin D supplies that reported on sun exposure and frequency of vitamin D&#x02013;relevant food consumption.</p></list-item><list-item><label>3.</label><p>The arbitrary dichotomization of the participants between low (25 to 50 nmol/L) and high (&#x0003e;50 to 75&#x000a0;nmol/L) strata based on screening s25OHD measurements that used an analytical method different than that applied to the samples collected during the 24&#x000a0;weeks of the trial. Nevertheless, this modification did not attenuate the marked difference in s25OHD between the 2 strata.</p></list-item><list-item><label>4.</label><p>The cohort was exclusively white and recruited in one single French region. Therefore, the results may not be the same for other ethnic groups or among populations with different dietary and lifestyle habits and/or living in regions at different latitudes and/or altitudes.</p></list-item></list>
</p></sec></sec><sec sec-type="conclusions" id="s0005"><title>Conclusions</title><p>This clinical trial in menopausal women provides data on 3 interdependent determinants of vitamin D status. It documents a dose&#x02013;response of vitamin D<sub>3</sub>&#x02013;fortified yogurt on the evolution of s25OHD during 4&#x000a0;months and the 2&#x000a0;months following discontinuation of the intervention. At the end of the intervention, the percentage of subjects with s25OHD &#x02265; 50&#x000a0;nmol/L was about 38, 55, and 64% in Gr.Suppl.0, Gr.Suppl.5, and Gr.Suppl.10, respectively. The study unequivocally demonstrates the marked influence of the initial vitamin D status on the absolute increase in s25OHD: the lower the baseline status, the higher the response to a given dose of supplemental VitD<sub>3</sub>. The trial was conducted from January to October of the same year, which highlighted the important influence of season on the magnitude of the s25OHD response to 2 doses of VitD<sub>3</sub>-fortified yogurt compared to the maintenance of dietary habits in a time-controlled group. Thus, this randomized controlled trial quantitatively documents the interaction of 3&#x000a0;key determinants of vitamin D status: supplemental doses, initial status, and seasonality.</p></sec></body><back><sec><title>Funding</title><p>Funding was provided by Yoplait France, Boulogne, France, and General Mills, Minneapolis, Minnesota.</p></sec><sec><title>Disclosure</title><p>J.P.B. is clinical consultant for General Mills-Yoplait; J.P.B. has no financial interest in the outcome of the reported clinical trial. F.D.-P. and B.R. are scientific collaborators of General Mills-Yoplait; E.R. is a former scientific collaborator of Yoplait France; and S.W. is scientific consultant for General Mills-Yoplait; S.W. has no financial interest in the outcome of the reported clinical trial.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cashman</surname><given-names>KD</given-names></name>, <name><surname>Seamans</surname><given-names>KM</given-names></name>, <name><surname>Lucey</surname><given-names>AJ</given-names></name>, <name><surname>Stocklin</surname><given-names>E</given-names></name>, <name><surname>Weber</surname><given-names>P</given-names></name>, <name><surname>Kiely</surname><given-names>M</given-names></name>, <name><surname>Hill</surname><given-names>TR</given-names></name></person-group>: <article-title>Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults</article-title>. <source>Am J Clin Nutr</source>
<volume>95</volume>:<fpage>1350</fpage>&#x02013;<lpage>1356</lpage>, <year>2012</year>.<pub-id pub-id-type="pmid">22552038</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dawson-Hughes</surname><given-names>B</given-names></name>, <name><surname>Mithal</surname><given-names>A</given-names></name>, <name><surname>Bonjour</surname><given-names>JP</given-names></name>, <name><surname>Boonen</surname><given-names>S</given-names></name>, <name><surname>Burckhardt</surname><given-names>P</given-names></name>, <name><surname>Fuleihan</surname><given-names>GE</given-names></name>, <name><surname>Josse</surname><given-names>RG</given-names></name>, <name><surname>Lips</surname><given-names>P</given-names></name>, <name><surname>Morales-Torres</surname><given-names>J</given-names></name>, <name><surname>Yoshimura</surname><given-names>N</given-names></name></person-group>: <article-title>IOF position statement: vitamin D recommendations for older adults</article-title>. <source>Osteoporos Int</source>
<volume>21</volume>:<fpage>1151</fpage>&#x02013;<lpage>1154</lpage>, <year>2010</year>.<pub-id pub-id-type="pmid">20422154</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Holick</surname><given-names>MF</given-names></name>, <name><surname>Binkley</surname><given-names>NC</given-names></name>, <name><surname>Bischoff-Ferrari</surname><given-names>HA</given-names></name>, <name><surname>Gordon</surname><given-names>CM</given-names></name>, <name><surname>Hanley</surname><given-names>DA</given-names></name>, <name><surname>Heaney</surname><given-names>RP</given-names></name>, <name><surname>Murad</surname><given-names>MH</given-names></name>, <name><surname>Weaver</surname><given-names>CM</given-names></name></person-group>: <article-title>Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited</article-title>. <source>J Clin Endocrinol Metab</source>
<volume>97</volume>:<fpage>1153</fpage>&#x02013;<lpage>1158</lpage>, <year>2012</year>.<pub-id pub-id-type="pmid">22442274</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ross</surname><given-names>AC</given-names></name>, <name><surname>Manson</surname><given-names>JE</given-names></name>, <name><surname>Abrams</surname><given-names>SA</given-names></name>, <name><surname>Aloia</surname><given-names>JF</given-names></name>, <name><surname>Brannon</surname><given-names>PM</given-names></name>, <name><surname>Clinton</surname><given-names>SK</given-names></name>, <name><surname>Durazo-Arvizu</surname><given-names>RA</given-names></name>, <name><surname>Gallagher</surname><given-names>JC</given-names></name>, <name><surname>Gallo</surname><given-names>RL</given-names></name>, <name><surname>Jones</surname><given-names>G</given-names></name>, et&#x000a0;al.</person-group>: <article-title>The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know</article-title>. <source>J Clin Endocrinol Metab</source>
<volume>96</volume>:<fpage>53</fpage>&#x02013;<lpage>58</lpage>, <year>2011</year>.<pub-id pub-id-type="pmid">21118827</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whiting</surname><given-names>SJ</given-names></name>, <name><surname>Bonjour</surname><given-names>JP</given-names></name>, <name><surname>Payen</surname><given-names>FD</given-names></name>, <name><surname>Rousseau</surname><given-names>B</given-names></name></person-group>: <article-title>Moderate amounts of vitamin D3 in supplements are effective in raising serum 25-hydroxyvitamin D from low baseline levels in adults: a systematic review</article-title>. <source>Nutrients</source>
<volume>7</volume>:<fpage>2311</fpage>&#x02013;<lpage>2323</lpage>, <year>2015</year>.<pub-id pub-id-type="pmid">25835074</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lips</surname><given-names>P</given-names></name></person-group>: <article-title>Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications</article-title>. <source>Endocr Rev</source>
<volume>22</volume>:<fpage>477</fpage>&#x02013;<lpage>501</lpage>, <year>2001</year>.<pub-id pub-id-type="pmid">11493580</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rolland</surname><given-names>Y</given-names></name>, <name><surname>de Souto Barreto</surname><given-names>P</given-names></name>, <name><surname>Abellan Van Kan</surname><given-names>G</given-names></name>, <name><surname>Annweiler</surname><given-names>C</given-names></name>, <name><surname>Beauchet</surname><given-names>O</given-names></name>, <name><surname>Bischoff-Ferrari</surname><given-names>H</given-names></name>, <name><surname>Berrut</surname><given-names>G</given-names></name>, <name><surname>Blain</surname><given-names>H</given-names></name>, <name><surname>Bonnefoy</surname><given-names>M</given-names></name>, <name><surname>Cesari</surname><given-names>M</given-names></name>, et&#x000a0;al.</person-group>: <article-title>Vitamin D supplementation in older adults: searching for specific guidelines in nursing homes</article-title>. <source>J Nutr Health Aging</source>
<volume>17</volume>:<fpage>402</fpage>&#x02013;<lpage>412</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23538667</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lips</surname><given-names>P</given-names></name>, <name><surname>van Schoor</surname><given-names>NM</given-names></name>, <name><surname>de Jongh</surname><given-names>RT</given-names></name></person-group>: <article-title>Diet, sun, and lifestyle as determinants of vitamin D status</article-title>. <source>Ann N Y Acad Sci</source>
<volume>1317</volume>:<fpage>92</fpage>&#x02013;<lpage>98</lpage>, <year>2014</year>.<pub-id pub-id-type="pmid">24814938</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boonen</surname><given-names>S</given-names></name>, <name><surname>Lips</surname><given-names>P</given-names></name>, <name><surname>Bouillon</surname><given-names>R</given-names></name>, <name><surname>Bischoff-Ferrari</surname><given-names>HA</given-names></name>, <name><surname>Vanderschueren</surname><given-names>D</given-names></name>, <name><surname>Haentjens</surname><given-names>P</given-names></name></person-group>: <article-title>Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials</article-title>. <source>J Clin Endocrinol Metab</source>
<volume>92</volume>:<fpage>1415</fpage>&#x02013;<lpage>1423</lpage>, <year>2007</year>.<pub-id pub-id-type="pmid">17264183</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bischoff-Ferrari</surname><given-names>HA</given-names></name></person-group>: <article-title>Vitamin D and fracture prevention</article-title>. <source>Endocrinol Metab Clin North Am</source>
<volume>39</volume>:<fpage>347</fpage>&#x02013;<lpage>353</lpage>, <year>2010</year>.<pub-id pub-id-type="pmid">20511056</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Holick</surname><given-names>MF</given-names></name>, <name><surname>Chen</surname><given-names>TC</given-names></name>, <name><surname>Lu</surname><given-names>Z</given-names></name>, <name><surname>Sauter</surname><given-names>E</given-names></name></person-group>: <article-title>Vitamin D and skin physiology: a D-lightful story</article-title>. <source>J Bone Miner Res</source>
<volume>22</volume>(<comment>Suppl</comment>
<issue>2</issue>):<fpage>V28</fpage>&#x02013;<lpage>V33</lpage>, <year>2007</year>.<pub-id pub-id-type="pmid">18290718</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kasahara</surname><given-names>AK</given-names></name>, <name><surname>Singh</surname><given-names>RJ</given-names></name>, <name><surname>Noymer</surname><given-names>A</given-names></name></person-group>: <article-title>Vitamin D (25OHD) serum seasonality in the United States</article-title>. <source>PLoS One</source>
<volume>8</volume>:<fpage>e65785</fpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23805188</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klenk</surname><given-names>J</given-names></name>, <name><surname>Rapp</surname><given-names>K</given-names></name>, <name><surname>Denkinger</surname><given-names>MD</given-names></name>, <name><surname>Nagel</surname><given-names>G</given-names></name>, <name><surname>Nikolaus</surname><given-names>T</given-names></name>, <name><surname>Peter</surname><given-names>R</given-names></name>, <name><surname>Koenig</surname><given-names>W</given-names></name>, <name><surname>Bohm</surname><given-names>BO</given-names></name>, <name><surname>Rothenbacher</surname><given-names>D</given-names></name></person-group>: <article-title>Seasonality of vitamin D status in older people in southern Germany: implications for assessment</article-title>. <source>Age Ageing</source>
<volume>42</volume>:<fpage>404</fpage>&#x02013;<lpage>408</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23542723</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Macdonald</surname><given-names>HM</given-names></name></person-group>: <article-title>Contributions of sunlight and diet to vitamin D status</article-title>. <source>Calcif Tissue Int</source>
<volume>92</volume>:<fpage>163</fpage>&#x02013;<lpage>176</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23001438</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lucas</surname><given-names>RM</given-names></name>, <name><surname>Norval</surname><given-names>M</given-names></name>, <name><surname>Neale</surname><given-names>RE</given-names></name>, <name><surname>Young</surname><given-names>AR</given-names></name>, <name><surname>de Gruijl</surname><given-names>FR</given-names></name>, <name><surname>Takizawa</surname><given-names>Y</given-names></name>, <name><surname>van der Leun</surname><given-names>JC</given-names></name></person-group>: <article-title>The consequences for human health of stratospheric ozone depletion in association with other environmental factors</article-title>. <source>Photochem Photobiol Sci</source>
<volume>14</volume>:<fpage>53</fpage>&#x02013;<lpage>87</lpage>, <year>2015</year>.<pub-id pub-id-type="pmid">25383760</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Engelsen</surname><given-names>O</given-names></name>, <name><surname>Brustad</surname><given-names>M</given-names></name>, <name><surname>Aksnes</surname><given-names>L</given-names></name>, <name><surname>Lund</surname><given-names>E</given-names></name></person-group>: <article-title>Daily duration of vitamin D synthesis in human skin with relation to latitude, total ozone, altitude, ground cover, aerosols and cloud thickness</article-title>. <source>Photochem Photobiol</source>
<volume>81</volume>:<fpage>1287</fpage>&#x02013;<lpage>1290</lpage>, <year>2005</year>.<pub-id pub-id-type="pmid">16354110</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Farrar</surname><given-names>MD</given-names></name>, <name><surname>Kift</surname><given-names>R</given-names></name>, <name><surname>Felton</surname><given-names>SJ</given-names></name>, <name><surname>Berry</surname><given-names>JL</given-names></name>, <name><surname>Durkin</surname><given-names>MT</given-names></name>, <name><surname>Allan</surname><given-names>D</given-names></name>, <name><surname>Vail</surname><given-names>A</given-names></name>, <name><surname>Webb</surname><given-names>AR</given-names></name>, <name><surname>Rhodes</surname><given-names>LE</given-names></name></person-group>: <article-title>Recommended summer sunlight exposure amounts fail to produce sufficient vitamin D status in UK adults of South Asian origin</article-title>. <source>Am J Clin Nutr</source>
<volume>94</volume>:<fpage>1219</fpage>&#x02013;<lpage>1224</lpage>, <year>2011</year>.<pub-id pub-id-type="pmid">21918215</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heaney</surname><given-names>RP</given-names></name>, <name><surname>Davies</surname><given-names>KM</given-names></name>, <name><surname>Chen</surname><given-names>TC</given-names></name>, <name><surname>Holick</surname><given-names>MF</given-names></name>, <name><surname>Barger-Lux</surname><given-names>MJ</given-names></name></person-group>: <article-title>Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol</article-title>. <source>Am J Clin Nutr</source>
<volume>77</volume>:<fpage>204</fpage>&#x02013;<lpage>210</lpage>, <year>2003</year>.<pub-id pub-id-type="pmid">12499343</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dawson-Hughes</surname><given-names>B</given-names></name>, <name><surname>Heaney</surname><given-names>RP</given-names></name>, <name><surname>Holick</surname><given-names>MF</given-names></name>, <name><surname>Lips</surname><given-names>P</given-names></name>, <name><surname>Meunier</surname><given-names>PJ</given-names></name>, <name><surname>Vieth</surname><given-names>R</given-names></name></person-group>: <article-title>Estimates of optimal vitamin D status</article-title>. <source>Osteoporos Int</source>
<volume>16</volume>:<fpage>713</fpage>&#x02013;<lpage>716</lpage>, <year>2005</year>.<pub-id pub-id-type="pmid">15776217</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bischoff-Ferrari</surname><given-names>HA</given-names></name>, <name><surname>Shao</surname><given-names>A</given-names></name>, <name><surname>Dawson-Hughes</surname><given-names>B</given-names></name>, <name><surname>Hathcock</surname><given-names>J</given-names></name>, <name><surname>Giovannucci</surname><given-names>E</given-names></name>, <name><surname>Willett</surname><given-names>WC</given-names></name></person-group>: <article-title>Benefit&#x02013;risk assessment of vitamin D supplementation</article-title>. <source>Osteoporos Int</source>
<volume>21</volume>:<fpage>1121</fpage>&#x02013;<lpage>1132</lpage>, <year>2010</year>.<pub-id pub-id-type="pmid">19957164</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heaney</surname><given-names>RP</given-names></name></person-group>: <article-title>Assessing vitamin D status</article-title>. <source>Curr Opin Clin Nutr Metab Care</source>
<volume>14</volume>:<fpage>440</fpage>&#x02013;<lpage>444</lpage>, <year>2011</year>.<pub-id pub-id-type="pmid">21832900</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>JC</given-names></name>, <name><surname>Sai</surname><given-names>A</given-names></name>, <name><surname>Templin</surname><given-names>T</given-names><suffix>II</suffix></name>, <name><surname>Smith</surname><given-names>L</given-names></name></person-group>: <article-title>Dose response to vitamin D supplementation in postmenopausal women: a randomized trial</article-title>. <source>Ann Intern Med</source>
<volume>156</volume>:<fpage>425</fpage>&#x02013;<lpage>437</lpage>, <year>2012</year>.<pub-id pub-id-type="pmid">22431675</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bouillon</surname><given-names>R</given-names></name>, <name><surname>Van Schoor</surname><given-names>NM</given-names></name>, <name><surname>Gielen</surname><given-names>E</given-names></name>, <name><surname>Boonen</surname><given-names>S</given-names></name>, <name><surname>Mathieu</surname><given-names>C</given-names></name>, <name><surname>Vanderschueren</surname><given-names>D</given-names></name>, <name><surname>Lips</surname><given-names>P</given-names></name></person-group>: <article-title>Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine</article-title>. <source>J Clin Endocrinol Metab</source>
<volume>98</volume>:<fpage>E1283</fpage>&#x02013;<lpage>E1304</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23922354</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>JC</given-names></name>, <name><surname>Yalamanchili</surname><given-names>V</given-names></name>, <name><surname>Smith</surname><given-names>LM</given-names></name></person-group>: <article-title>The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women</article-title>. <source>J Steroid Biochem Mol Biol</source>
<volume>136</volume>:<fpage>195</fpage>&#x02013;<lpage>200</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23246640</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mazahery</surname><given-names>H</given-names></name>, <name><surname>von Hurst</surname><given-names>PR</given-names></name></person-group>: <article-title>Factors affecting 25-hydroxyvitamin D concentration in response to vitamin D supplementation</article-title>. <source>Nutrients</source>. <volume>7</volume>:<fpage>5111</fpage>&#x02013;<lpage>5142</lpage>, <year>2015</year>.<pub-id pub-id-type="pmid">26121531</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sollid</surname><given-names>ST</given-names></name>, <name><surname>Hutchinson</surname><given-names>MY</given-names></name>, <name><surname>Fuskevag</surname><given-names>OM</given-names></name>, <name><surname>Joakimsen</surname><given-names>RM</given-names></name>, <name><surname>Jorde</surname><given-names>R</given-names></name></person-group>: <article-title>Large individual differences in serum 25-hydroxyvitamin D response to vitamin D supplementation: effects of genetic factors, body mass index, and baseline concentration</article-title>. <source>Results from a randomized controlled trial. Horm Metab Res</source>
<volume>48</volume>:<fpage>27</fpage>&#x02013;<lpage>34</lpage>, <year>2016</year>.<pub-id pub-id-type="pmid">25702786</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rees</surname><given-names>JR</given-names></name>, <name><surname>Mott</surname><given-names>LA</given-names></name>, <name><surname>Barry</surname><given-names>EL</given-names></name>, <name><surname>Baron</surname><given-names>JA</given-names></name>, <name><surname>Bostick</surname><given-names>RM</given-names></name>, <name><surname>Figueiredo</surname><given-names>JC</given-names></name>, <name><surname>Bresalier</surname><given-names>RS</given-names></name>, <name><surname>Robertson</surname><given-names>DJ</given-names></name>, <name><surname>Peacock</surname><given-names>JL</given-names></name></person-group>: <article-title>Lifestyle and other factors explain one-half of the variability in the serum 25-hydroxyvitamin D response to cholecalciferol supplementation in healthy adults</article-title>. <source>J Nutr</source>
<volume>146</volume>:<fpage>2312</fpage>&#x02013;<lpage>2324</lpage>, <year>2016</year>.<pub-id pub-id-type="pmid">27683872</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garabedian</surname><given-names>M</given-names></name>, <name><surname>Menn</surname><given-names>S</given-names></name>, <name><surname>Walrant-Debray</surname><given-names>O</given-names></name>, <name><surname>Teinturier</surname><given-names>C</given-names></name>, <name><surname>Delaveyne</surname><given-names>R</given-names></name>, <name><surname>Roden</surname><given-names>A</given-names></name></person-group>: <article-title>Prevention of child and adolescent vitamin D deficiency</article-title>. <source>II. Validation of a decision-making abacus based on sun exposure and vitamin D intakes. Arch Pediatr</source>
<volume>12</volume>:<fpage>410</fpage>&#x02013;<lpage>419</lpage>, <year>2005</year>.</mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Viljakainen</surname><given-names>HT</given-names></name>, <name><surname>Palssa</surname><given-names>A</given-names></name>, <name><surname>Karkkainen</surname><given-names>M</given-names></name>, <name><surname>Jakobsen</surname><given-names>J</given-names></name>, <name><surname>Lamberg-Allardt</surname><given-names>C</given-names></name></person-group>: <article-title>How much vitamin D3 do the elderly need</article-title>? <source>J Am Coll Nutr</source>
<volume>25</volume>:<fpage>429</fpage>&#x02013;<lpage>435</lpage>, <year>2006</year>.<pub-id pub-id-type="pmid">17031013</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Black</surname><given-names>LJ</given-names></name>, <name><surname>Seamans</surname><given-names>KM</given-names></name>, <name><surname>Cashman</surname><given-names>KD</given-names></name>, <name><surname>Kiely</surname><given-names>M</given-names></name></person-group>: <article-title>An updated systematic review and meta-analysis of the efficacy of vitamin D food fortification</article-title>. <source>J Nutr</source>
<volume>142</volume>:<fpage>1102</fpage>&#x02013;<lpage>1108</lpage>, <year>2012</year>.<pub-id pub-id-type="pmid">22513988</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bikle</surname><given-names>DD</given-names></name></person-group>: <article-title>Vitamin D metabolism, mechanism of action, and clinical applications</article-title>. <source>Chem Biol</source>
<volume>21</volume>:<fpage>319</fpage>&#x02013;<lpage>329</lpage>, <year>2014</year>.<pub-id pub-id-type="pmid">24529992</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>JCY</given-names></name>, <name><surname>Nicholls</surname><given-names>H</given-names></name>, <name><surname>Piec</surname><given-names>I</given-names></name>, <name><surname>Washbourne</surname><given-names>CJ</given-names></name>, <name><surname>Dutton</surname><given-names>JJ</given-names></name>, <name><surname>Jackson</surname><given-names>S</given-names></name>, <name><surname>Greeves</surname><given-names>J</given-names></name>, <name><surname>Fraser</surname><given-names>WD</given-names></name></person-group>: <article-title>Reference intervals for serum 24,25-dihydroxyvitamin D and the ratio with 25-hydroxyvitamin D established using a newly developed LC-MS/MS method</article-title>. <source>J Nutr Biochem</source>
<volume>46</volume>:<fpage>21</fpage>&#x02013;<lpage>29</lpage>, <year>2017</year>.<pub-id pub-id-type="pmid">28437713</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>R</given-names></name>, <name><surname>Chun</surname><given-names>RF</given-names></name>, <name><surname>Lisse</surname><given-names>TS</given-names></name>, <name><surname>Garcia</surname><given-names>AJ</given-names></name>, <name><surname>Xu</surname><given-names>J</given-names></name>, <name><surname>Adams</surname><given-names>JS</given-names></name>, <name><surname>Hewison</surname><given-names>M</given-names></name></person-group>: <article-title>Vitamin D and alternative splicing of RNA</article-title>. <source>J Steroid Biochem Mol Biol</source>
<volume>148</volume>:<fpage>310</fpage>&#x02013;<lpage>317</lpage>, <year>2015</year>.<pub-id pub-id-type="pmid">25447737</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McKenna</surname><given-names>MJ</given-names></name>, <name><surname>Murray</surname><given-names>BF</given-names></name></person-group>: <article-title>Vitamin D dose response is underestimated by Endocrine Society's Clinical Practice Guideline</article-title>. <source>Endocr Connect</source>
<volume>2</volume>:<fpage>87</fpage>&#x02013;<lpage>95</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23781324</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Lips</surname><given-names>P</given-names></name>, <name><surname>van Shoor</surname><given-names>NM</given-names></name>, <name><surname>Bravenhoer</surname><given-names>N</given-names></name></person-group>: <article-title>Vitamin D&#x02013;related disorders</article-title>. In <person-group person-group-type="editor"><name><surname>Rosen</surname><given-names>CJ</given-names></name>, <name><surname>Compston</surname><given-names>JE</given-names></name>, <name><surname>Lian</surname><given-names>JB</given-names></name></person-group> (eds): &#x0201c;<source>Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism</source>,&#x0201d; <edition>7th</edition>
<publisher-name>The American Society for Bone and Mineral Research</publisher-name>, <fpage>329</fpage>&#x02013;<lpage>335</lpage>, <year>2009</year>.</mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whiting</surname><given-names>SJ</given-names></name>, <name><surname>Kohrt</surname><given-names>WM</given-names></name>, <name><surname>Warren</surname><given-names>MP</given-names></name>, <name><surname>Kraenzlin</surname><given-names>MI</given-names></name>, <name><surname>Bonjour</surname><given-names>JP</given-names></name></person-group>: <article-title>Food fortification for bone health in adulthood: a scoping review</article-title>. <source>Eur J Clin Nutr</source>
<volume>70</volume>:<fpage>1099</fpage>&#x02013;<lpage>1105</lpage>, <year>2016</year>.<pub-id pub-id-type="pmid">27026430</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rossini</surname><given-names>M</given-names></name>, <name><surname>Bianchi</surname><given-names>G</given-names></name>, <name><surname>Di Munno</surname><given-names>O</given-names></name>, <name><surname>Giannini</surname><given-names>S</given-names></name>, <name><surname>Minisola</surname><given-names>S</given-names></name>, <name><surname>Sinigaglia</surname><given-names>L</given-names></name>, <name><surname>Adami</surname><given-names>S</given-names></name></person-group>: <article-title>Determinants of adherence to osteoporosis treatment in clinical practice</article-title>. <source>Osteoporos Int</source>
<volume>17</volume>:<fpage>914</fpage>&#x02013;<lpage>921</lpage>, <year>2006</year>.<pub-id pub-id-type="pmid">16538553</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanders</surname><given-names>KM</given-names></name>, <name><surname>Stuart</surname><given-names>AL</given-names></name>, <name><surname>Williamson</surname><given-names>EJ</given-names></name>, <name><surname>Simpson</surname><given-names>JA</given-names></name>, <name><surname>Kotowicz</surname><given-names>MA</given-names></name>, <name><surname>Young</surname><given-names>D</given-names></name>, <name><surname>Nicholson</surname><given-names>GC</given-names></name></person-group>: <article-title>Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial</article-title>. <source>JAMA</source>
<volume>303</volume>:<fpage>1815</fpage>&#x02013;<lpage>1822</lpage>, <year>2010</year>.<pub-id pub-id-type="pmid">20460620</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosen</surname><given-names>CJ</given-names></name>, <name><surname>Abrams</surname><given-names>SA</given-names></name>, <name><surname>Aloia</surname><given-names>JF</given-names></name>, <name><surname>Brannon</surname><given-names>PM</given-names></name>, <name><surname>Clinton</surname><given-names>SK</given-names></name>, <name><surname>Durazo-Arvizu</surname><given-names>RA</given-names></name>, <name><surname>Gallagher</surname><given-names>JC</given-names></name>, <name><surname>Gallo</surname><given-names>RL</given-names></name>, <name><surname>Jones</surname><given-names>G</given-names></name>, <name><surname>Kovacs</surname><given-names>CS</given-names></name>, et&#x000a0;al.</person-group>: <article-title>IOM committee members respond to Endocrine Society vitamin D guideline</article-title>. <source>J Clin Endocrinol Metab</source>
<volume>97</volume>:<fpage>1146</fpage>&#x02013;<lpage>1152</lpage>, <year>2012</year>.<pub-id pub-id-type="pmid">22442278</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cashman</surname><given-names>KD</given-names></name>, <name><surname>Kiely</surname><given-names>M</given-names></name></person-group>: <article-title>Tackling inadequate vitamin D intakes within the population: fortification of dairy products with vitamin D may not be enough</article-title>. <source>Endocrine</source>
<volume>51</volume>:<fpage>38</fpage>&#x02013;<lpage>46</lpage>, <year>2016</year>.<pub-id pub-id-type="pmid">26260695</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ginde</surname><given-names>AA</given-names></name>, <name><surname>Scragg</surname><given-names>R</given-names></name>, <name><surname>Schwartz</surname><given-names>RS</given-names></name>, <name><surname>Camargo CA</surname><given-names>Jr</given-names></name></person-group>: <article-title>Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S</article-title>. <source>adults. J Am Geriatr Soc</source>
<volume>57</volume>:<fpage>1595</fpage>&#x02013;<lpage>1603</lpage>, <year>2009</year>.<pub-id pub-id-type="pmid">19549021</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zittermann</surname><given-names>A</given-names></name>, <name><surname>Iodice</surname><given-names>S</given-names></name>, <name><surname>Pilz</surname><given-names>S</given-names></name>, <name><surname>Grant</surname><given-names>WB</given-names></name>, <name><surname>Bagnardi</surname><given-names>V</given-names></name>, <name><surname>Gandini</surname><given-names>S</given-names></name></person-group>: <article-title>Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies</article-title>. <source>Am J Clin Nutr</source>
<volume>95</volume>:<fpage>91</fpage>&#x02013;<lpage>100</lpage>, <year>2012</year>.<pub-id pub-id-type="pmid">22170374</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garland</surname><given-names>CF</given-names></name>, <name><surname>Kim</surname><given-names>JJ</given-names></name>, <name><surname>Mohr</surname><given-names>SB</given-names></name>, <name><surname>Gorham</surname><given-names>ED</given-names></name>, <name><surname>Grant</surname><given-names>WB</given-names></name>, <name><surname>Giovannucci</surname><given-names>EL</given-names></name>, <name><surname>Baggerly</surname><given-names>L</given-names></name>, <name><surname>Hofflich</surname><given-names>H</given-names></name>, <name><surname>Ramsdell</surname><given-names>JW</given-names></name>, <name><surname>Zeng</surname><given-names>K</given-names></name>, et&#x000a0;al.</person-group>: <article-title>Meta-analysis of all-cause mortality according to serum 25-hydroxyvitamin D</article-title>. <source>Am J Public Health</source>
<volume>104</volume>:<fpage>e43</fpage>&#x02013;<lpage>e50</lpage>, <year>2014</year>.</mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tomson</surname><given-names>J</given-names></name>, <name><surname>Emberson</surname><given-names>J</given-names></name>, <name><surname>Hill</surname><given-names>M</given-names></name>, <name><surname>Gordon</surname><given-names>A</given-names></name>, <name><surname>Armitage</surname><given-names>J</given-names></name>, <name><surname>Shipley</surname><given-names>M</given-names></name>, <name><surname>Collins</surname><given-names>R</given-names></name>, <name><surname>Clarke</surname><given-names>R</given-names></name></person-group>: <article-title>Vitamin D and risk of death from vascular and non-vascular causes in the Whitehall study and meta-analyses of 12,000 deaths</article-title>. <source>Eur Heart J</source>
<volume>34</volume>:<fpage>1365</fpage>&#x02013;<lpage>1374</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23257953</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clarke</surname><given-names>R</given-names></name>, <name><surname>Newman</surname><given-names>C</given-names></name>, <name><surname>Tomson</surname><given-names>J</given-names></name>, <name><surname>Hin</surname><given-names>H</given-names></name>, <name><surname>Kurien</surname><given-names>R</given-names></name>, <name><surname>Cox</surname><given-names>J</given-names></name>, <name><surname>Lay</surname><given-names>M</given-names></name>, <name><surname>Sayer</surname><given-names>J</given-names></name>, <name><surname>Hill</surname><given-names>M</given-names></name>, <name><surname>Emberson</surname><given-names>J</given-names></name>, et&#x000a0;al.</person-group>: <article-title>Estimation of the optimum dose of vitamin D for disease prevention in older people: rationale, design and baseline characteristics of the BEST-D trial</article-title>. <source>Maturitas</source>
<volume>80</volume>:<fpage>426</fpage>&#x02013;<lpage>431</lpage>, <year>2015</year>.<pub-id pub-id-type="pmid">25721698</pub-id></mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hin</surname><given-names>H</given-names></name>, <name><surname>Tomson</surname><given-names>J</given-names></name>, <name><surname>Newman</surname><given-names>C</given-names></name>, <name><surname>Kurien</surname><given-names>R</given-names></name>, <name><surname>Lay</surname><given-names>M</given-names></name>, <name><surname>Cox</surname><given-names>J</given-names></name>, <name><surname>Sayer</surname><given-names>J</given-names></name>, <name><surname>Hill</surname><given-names>M</given-names></name>, <name><surname>Emberson</surname><given-names>J</given-names></name>, <name><surname>Armitage</surname><given-names>J</given-names></name>, et&#x000a0;al.</person-group>: <article-title>Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care</article-title>. <source>Osteoporos Int</source>
<volume>28</volume>:<fpage>841</fpage>&#x02013;<lpage>851</lpage>, <year>2017</year>.<pub-id pub-id-type="pmid">27986983</pub-id></mixed-citation></ref></ref-list></back></article>